Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 1/20 | 0.47 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.47 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | STS | P08842 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CASP1 | P29466 | 1/20 | 0.45 |
| ▸ | CASP7 | P55210 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20776763 | 0.97 | HSD17B10 (0.48) | ADRA2AADRA2BADRA2CTSHRSTS | |
| SCHEMBL21765305 | 0.97 | HSD17B10 (0.48) | ADRA2AADRA2BADRA2CTSHRSTS | |
| SCHEMBL7967652 | 0.97 | HSD17B10 (0.48) | ADRA2AADRA2BADRA2CTSHRSTS | |
| SCHEMBL18410108 | 0.97 | HSD17B10 (0.48) | ADRA2AADRA2BADRA2CTSHRSTS | |
| SCHEMBL4684525 | 0.97 | HSD17B10 (0.48) | ADRA2AADRA2BADRA2CTSHRSTS | |
| Hydrochloric Acid SCHEMBL8980397 | 0.97 | ADRA2A (0.45) | ADRA2AADRA2BADRA2CTSHRSTS | |
| SCHEMBL21033028 | 0.97 | HSD17B10 (0.48) | ADRA2AADRA2BADRA2CTSHRSTS | |
| SCHEMBL42805 | 0.95 | CA12 (0.48) | ADRA2AADRA2BADRA2CTSHRSTS | |
| SCHEMBL29779691 | 0.95 | CA12 (0.48) | ADRA2AADRA2BADRA2CTSHRSTS | |
| Hydrochloric Acid SCHEMBL2476978 | 0.92 | CA12 (0.47) | ADRA2AADRA2BADRA2CTSHRSTS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 608 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119371395-A | Ticagrelor Process for the preparation of intermediates | 江苏柯菲平医药股份有限公司 | 2025-01-28 | — | — | CN | claimed |
| CN-112159357-B | Refining method of caprolactam | 浙江恒逸石化研究院有限公司 | 2023-05-23 | — | — | CN | claimed |
| US-11459302-B2 | Refining process and refining system of caprolactam | Zhejiang Hengyi Petrochemical Research Institute Co., Ltd. (CN) | 2022-10-04 | — | — | US | claimed |
| CN-112142637-B | Method and system for refining caprolactam | 浙江恒逸石化研究院有限公司 | 2022-09-02 | — | — | CN | claimed |
| US-20220089545-A1 | REFINING PROCESS AND REFINING SYSTEM OF CAPROLACTAM | ZHEJIANG HENGLAN SCIENCE & TECHNOLOGY CO., LTD. (CN) | 2022-03-24 | — | — | US | claimed |
| CN-112159357-A | Refining method of caprolactam | 浙江恒澜科技有限公司 | 2021-01-01 | — | — | CN | claimed |
| CN-112142637-A | Method and system for refining caprolactam | 浙江恒澜科技有限公司 | 2020-12-29 | — | — | CN | claimed |
| CN-112079760-A | Method and system for refining caprolactam | 浙江恒澜科技有限公司 | 2020-12-15 | — | — | CN | claimed |
| US-10696611-B2 | Adamantane derivative compound | AMOREPACIFIC CORPORATION (KR) | 2020-06-30 | — | — | US | claimed |
| US-20170283347-A1 | NOVEL ADAMANTANE DERIVATIVE COMPOUND | AMOREPACIFIC CORPORATION (KR) | 2017-10-05 | — | — | US | claimed |
| EP-3187486-A1 | NOVEL ADAMANTANE DERIVATIVE COMPOUND | Amorepacific Corporation (KR) | 2017-07-05 | — | — | EP | claimed |
| EP-2074089-B1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2013-09-18 | — | — | EP | claimed |
| US-8222248-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-07-17 | — | — | US | claimed |
| WO-2009135925-A1 | SUBSTITUTED N-IMIDAZO[2,1-B]THIAZOLE-5-SULFONAMIDE DERIVATIVES AS 5-HT6 LIGANDS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-11-12 | — | — | WO | claimed |
| WO-2009135927-A1 | SUBSTITUTED N-PHENYL-2,3-DIHYDROIMIDAZO[2,1-B]THIAZOLE-5-SULFONAMIDE DERIVATIVES AS 5-HT6 LIGANDS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-11-12 | — | — | WO | claimed |
| EP-2116547-A1 | Substituted N-imidazo(2, 1-b) thiazole-5-sulfonamide derivatives as 5-TH6 ligands | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2009-11-11 | — | — | EP | claimed |
| EP-2116546-A1 | Substituted N-phenyl-2,3-dihydroimidazo[2,1-b]thiazole-5-sulfonamide derivatives as 5-HT6 ligands | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2009-11-11 | — | — | EP | claimed |
| EP-0598122-A1 | ATTRACTING AND INGESTION-STIMULATING AGENT FOR COCKROACH | TAISHO PHARMACEUTICAL CO. LTD (JP) | 1994-05-25 | — | — | EP | claimed |
| WO-1993002554-A1 | ATTRACTING AND INGESTION-STIMULATING AGENT FOR COCKROACH | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 1993-02-18 | — | — | WO | claimed |
| JP-5194107-A | — | — | None | — | — | JP | disclosed |
| EP-3515892-B1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2026-04-15 | — | — | EP | disclosed |
| EP-4683909-A2 | ATM KINASE INHIBITORS | Eberhard Karls Universität Tübingen (DE) | 2026-01-28 | — | — | EP | disclosed |
| US-20260015328-A1 | ATM KINASE INHIBITORS | EBERHARD KARLS UNIVERSITÄT TÜBINGEN (DE) | 2026-01-15 | — | — | US | disclosed |
| US-20250179087-A1 | COMPOUNDS AND THEIR USES AS LPAR5 ANTAGONISTS | Immunophage Biotech (Shanghai) Co., Ltd. (CN) | 2025-06-05 | — | — | US | disclosed |
| EP-3758947-B1 | HEAT SENSITIVE RECORDING MATERIAL AND COLOR DEVELOPER | SOLENIS TECHNOLOGIES CAYMAN LP (KY) | 2025-05-14 | — | — | EP | disclosed |
| CN-119403800-A | Compounds and their use as LPAR5 antagonists | 艾美斐生物医药科技(上海)有限公司 | 2025-02-07 | — | — | CN | disclosed |
| CN-119371395-A | Ticagrelor Process for the preparation of intermediates | 江苏柯菲平医药股份有限公司 | 2025-01-28 | — | — | CN | disclosed |
| EP-4486742-A1 | COMPOUNDS AND THEIR USES AS LPAR5 ANTAGONISTS | IMMUNOPHAGE BIOTECH (SHANGHAI) CO., LTD. (CN) | 2025-01-08 | — | — | EP | disclosed |
| WO-2024240155-A1 | DIKETONE COMPOUNDS, PREPARATION METHOD THEREFOR AND USE THEREOF | 苏州大学 | 2024-11-28 | — | — | WO | disclosed |
| CN-118994100-A | Diketone compound and preparation method and application thereof | 苏州大学 | 2024-11-22 | — | — | CN | disclosed |
| US-20240360142-A1 | Multitargeting Agents For The Potential Treatment of Dementia With Lewy Bodies, Parkinson's Disease, and Alzheimer Disease With Lewy Bodies | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT | 2024-10-31 | — | — | US | disclosed |
| WO-2024215771-A1 | SUBSTITUTED PHENYL ETHYNYL PYRIMIDINES AS POTENT INHIBITORS OF ALPHAVIRUSES | SOUTHERN RESEARCH INSTITUTE (US) | 2024-10-17 | — | — | WO | disclosed |
| US-20240343707-A1 | SUBSTITUTED PHENYL ETHYNYL PYRIMIDINES AS POTENT INHIBITORS OF ALPHAVIRUSES | SOUTHERN RESEARCH INSTITUTE | 2024-10-17 | — | — | US | disclosed |
| US-12110292-B2 | Ligands to cereblon (CRBN) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-10-08 | — | — | US | disclosed |
| WO-2024206939-A2 | SARS-COV-2 ENTRY INHIBITORS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2024-10-03 | — | — | WO | disclosed |
| US-20240327388-A1 | QUINOLINAMINE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN PHARMACEUTICALS | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) | 2024-10-03 | — | — | US | disclosed |
| WO-2024194460-A2 | ATM KINASE INHIBITORS | EBERHARD KARLS UNIVERSITAET TUEBINGEN MEDIZINISCHE FAKULTAET (DE) | 2024-09-26 | — | — | WO | disclosed |
| EP-4434972-A1 | ATM KINASE INHIBITORS | Eberhard-Karls-Universität Tübingen (DE) | 2024-09-25 | — | — | EP | disclosed |
| CN-118591528-A | Quinoline amine compound, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2024-09-03 | — | — | CN | disclosed |
| US-12065421-B2 | Inhibitors of oplophorus luciferase-derived bioluminescent complexes | PROMEGA CORPORATION (US) | 2024-08-20 | — | — | US | disclosed |
| EP-4395500-A1 | LIGHT-EMITTING DEVICE AND ELECTRONIC APPARATUS INCLUDING THE SAME | Samsung Electronics Co., Ltd. (KR) | 2024-07-03 | — | — | EP | disclosed |
| EP-4395499-A1 | LIGHT-EMITTING DEVICE AND ELECTRONIC APPARATUS INCLUDING THE SAME | Samsung Electronics Co., Ltd. (KR) | 2024-07-03 | — | — | EP | disclosed |
| EP-3862360-B1 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE | SAMSUNG ELECTRONICS CO LTD (KR) | 2024-07-03 | — | — | EP | disclosed |
| CN-112638380-B | Cerebellar protein (CRBN) ligands | 达纳-法伯癌症研究所有限公司 | 2024-05-24 | — | — | CN | disclosed |
| EP-4140991-B1 | INHIBITORS OF OPLOPHORUS LUCIFERASE-DERIVED BIOLUMINESCENT COMPLEXES | PROMEGA CORP (US) | 2024-05-15 | — | — | EP | disclosed |
| CN-115160320-B | Preparation method of chiral pyrimido triazole ticagrelor | 南通常佑药业科技有限公司 | 2024-05-07 | — | — | CN | disclosed |
| CN-113727985-B | Compound and organic light emitting device comprising the same | 株式会社LG化学 | 2024-04-16 | — | — | CN | disclosed |
| EP-4349831-A1 | QUINOLINAMINE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN PHARMACEUTICALS | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2024-04-10 | — | — | EP | disclosed |
| US-20240092815-A1 | ORGANOMETALLIC COMPOUND, LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE LIGHT-EMITTING DEVICE | SAMSUNG DISPLAY CO., LTD. (KR) | 2024-03-21 | — | — | US | disclosed |
| US-20240083895-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2024-03-14 | — | — | US | disclosed |
| US-11925637-B2 | Phenylpiperazine proprotein convertase subtilisin/kexin type 9 (PCSK9) modulators and their use | SRX CARDIO, LLC (US) | 2024-03-12 | — | — | US | disclosed |
| WO-2024039222-A1 | COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING SAME | 주식회사 엘지화학 | 2024-02-22 | — | — | WO | disclosed |
| US-20240059703-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE | AMGEN INC. | 2024-02-22 | — | — | US | disclosed |
| US-20240059658-A1 | QUINOLINE DERIVATIVES AND USES IN MANAGING CANCER | UNIV EMORY (US) | 2024-02-22 | — | — | US | disclosed |
| CN-117529202-A | Organometallic compound, light-emitting device, electronic apparatus, and electronic device | 三星显示有限公司 | 2024-02-06 | — | — | CN | disclosed |
| CN-117510479-A | Preparation method of ticagrelor intermediate I | 江苏普润生物医药有限公司 | 2024-02-06 | — | — | CN | disclosed |
| US-11891369-B2 | Compounds for binding proprotein convertase subtilisin/kexin type 9 | SRX CARDIO, LLC (US) | 2024-02-06 | — | — | US | disclosed |
| EP-4306612-A1 | HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE | Samsung Electronics Co., Ltd. (KR) | 2024-01-17 | — | — | EP | disclosed |
| CN-117222639-A | Quinoline amine compound, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2023-12-12 | — | — | CN | disclosed |
| US-20230391730-A1 | INHIBITORS OF THE BROMODOMAIN PHD FINGER TRANSCRIPTION FACTOR (BPTF) AS ANTI-CANCER AGENTS | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2023-12-07 | — | — | US | disclosed |
| EP-4282933-A1 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE | Samsung Electronics Co., Ltd. (KR) | 2023-11-29 | — | — | EP | disclosed |
| US-20230371357-A1 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-11-16 | — | — | US | disclosed |
| EP-4273125-A1 | HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE | Samsung Electronics Co., Ltd. (KR) | 2023-11-08 | — | — | EP | disclosed |
| EP-4274405-A1 | LIGHT-EMITTING DEVICE AND ELECTRONIC APPARATUS INCLUDING THE SAME | Samsung Electronics Co., Ltd. (KR) | 2023-11-08 | — | — | EP | disclosed |
| EP-4274404-A1 | ORGANIC LIGHT-EMITTING DEVICE AND ELECTRONIC APPARATUS INCLUDING THE SAME | Samsung Electronics Co., Ltd. (KR) | 2023-11-08 | — | — | EP | disclosed |
| EP-4273127-A1 | HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE | Samsung Electronics Co., Ltd. (KR) | 2023-11-08 | — | — | EP | disclosed |
| EP-4273206-A1 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE | Samsung Electronics Co., Ltd. (KR) | 2023-11-08 | — | — | EP | disclosed |
| EP-4273126-A1 | HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE | Samsung Electronics Co., Ltd. (KR) | 2023-11-08 | — | — | EP | disclosed |
| CN-110392678-B | Compounds and methods for IDO and TDO modulation, and indications therefor | 普莱希科公司 | 2023-10-20 | — | — | CN | disclosed |
| EP-3187486-B1 | NOVEL ADAMANTANE DERIVATIVE COMPOUND | AMOREPACIFIC CORP (KR) | 2023-10-18 | — | — | EP | disclosed |
| US-20230312575-A1 | LIGANDS TO CEREBLON (CRBN) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-10-05 | — | — | US | disclosed |
| US-20230287005-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-09-14 | — | — | US | disclosed |
| US-20230287005-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-09-14 | — | — | US | disclosed |
| EP-4231806-A1 | ORGANIC LIGHT-EMITTING DEVICE AND ELECTRONIC APPARATUS INCLUDING THE SAME | Samsung Electronics Co., Ltd. (KR) | 2023-08-23 | — | — | EP | disclosed |
| EP-3620460-B1 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND DIAGNOSTIC COMPOSITION INCLUDING THE ORGANOMETALLIC COMPOUND | SAMSUNG ELECTRONICS CO LTD (KR) | 2023-08-16 | — | — | EP | disclosed |
| WO-2023138657-A1 | QUINOLINE AMINE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE | 江苏恒瑞医药股份有限公司 | 2023-07-27 | — | — | WO | disclosed |
| CN-116490201-A | Inhibitors of YAP/TAZ-TEAD tumor proteins, their synthesis and use | 布里奇恩生物科学公司 | 2023-07-25 | — | — | CN | disclosed |
| US-20230217805-A1 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-07-06 | — | — | US | disclosed |
| WO-2023122298-A1 | PROTEIN STABILIZING COMPOUNDS CONTAINING USP28 AND/OR USP25 TARGETING LIGANDS | Stablix, Inc. (US) | 2023-06-29 | — | — | WO | disclosed |
| EP-4203661-A1 | LIGHT-EMITTING DEVICE AND ELECTRONIC APPARATUS INCLUDING THE SAME | Samsung Electronics Co., Ltd. (KR) | 2023-06-28 | — | — | EP | disclosed |
| CN-116326241-A | Compound and organic light emitting device comprising the same | 株式会社LG化学 | 2023-06-23 | — | — | CN | disclosed |
| EP-4198164-A1 | MIXED LAYER, METHOD OF PREPARING THE MIXED LAYER, LIGHT-EMITTING DEVICE, AND ELECTRONIC APPARATUS | Samsung Electronics Co., Ltd. (KR) | 2023-06-21 | — | — | EP | disclosed |
| WO-2023106310-A1 | AROMATIC HETEROCYCLIC DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST ACTIVITY | 塩野義製薬株式会社 | 2023-06-15 | — | — | WO | disclosed |
| EP-3251128-B1 | FORMULATIONS WITH A LOW PARTICLE CONTENT | MERCK PATENT GMBH (DE) | 2023-06-14 | — | — | EP | disclosed |
| EP-3215510-B1 | SUBSTITUTED IMIDAZO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL R&D INVEST S A (PT) | 2023-06-07 | — | — | EP | disclosed |
| CN-112159357-B | Refining method of caprolactam | 浙江恒逸石化研究院有限公司 | 2023-05-23 | — | — | CN | disclosed |
| WO-2023085670-A1 | NOVEL COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | 주식회사 엘지화학 | 2023-05-19 | — | — | WO | disclosed |
| US-20230130176-A1 | ORGANIC MOLECULES FOR OPTOELECTRONIC DEVICES | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-04-27 | — | — | US | disclosed |
| US-11618749-B2 | Compounds and compositions for treating conditions associated with STING activity | IFM DUE, INC. (US) | 2023-04-04 | — | — | US | disclosed |
| EP-4140991-A1 | INHIBITORS OF OPLOPHORUS LUCIFERASE-DERIVED BIOLUMINESCENT COMPLEXES | Promega Corporation (US) | 2023-03-01 | — | — | EP | disclosed |
| US-11572341-B2 | Biguanide compound and use thereof | IMMUNOMET THERAPEUTICS INC. (US) | 2023-02-07 | — | — | US | disclosed |
| EP-4106032-A1 | LIGHT-EMITTING DEVICE AND ELECTRONIC APPARATUS INCLUDING THE SAME | Samsung Electronics Co., Ltd. (KR) | 2022-12-21 | — | — | EP | disclosed |
| US-11530219-B2 | Ligands to cereblon (CRBN) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| EP-3715355-B1 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE | SAMSUNG ELECTRONICS CO LTD (KR) | 2022-12-14 | — | — | EP | disclosed |
| EP-4102590-A2 | COMPOSITION, LAYER INCLUDING THE COMPOSITION, LIGHT-EMITTING DEVICE INCLUDING THE COMPOSITION, AND ELECTRONIC APPARATUS INCLUDING THE LIGHT-EMITTING DEVICE | Samsung Electronics Co., Ltd. (KR) | 2022-12-14 | — | — | EP | disclosed |
| EP-4101908-A1 | COMPOSITION, LAYER INCLUDING THE COMPOSITION, LIGHT-EMITTING DEVICE INCLUDING THE COMPOSITION, AND ELECTRONIC APPARATUS INCLUDING THE LIGHT-EMITTING DEVICE | Samsung Electronics Co., Ltd. (KR) | 2022-12-14 | — | — | EP | disclosed |
| EP-4097112-A1 | ORGANIC MOLECULES FOR OPTOELECTRONIC DEVICES | Samsung Display Co., Ltd. (KR) | 2022-12-07 | — | — | EP | disclosed |
| EP-4099413-A1 | COMPOSITION, LAYER INCLUDING THE COMPOSITION, LIGHT-EMITTING DEVICE INCLUDING THE COMPOSITION, AND ELECTRONIC APPARATUS INCLUDING THE LIGHT-EMITTING DEVICE | Samsung Electronics Co., Ltd. (KR) | 2022-12-07 | — | — | EP | disclosed |
| EP-4099420-A1 | COMPOSITION, LAYER INCLUDING THE COMPOSITION, LIGHT-EMITTING DEVICE INCLUDING THE COMPOSITION, AND ELECTRONIC APPARATUS INCLUDING THE LIGHT-EMITTING DEVICE | Samsung Electronics Co., Ltd. (KR) | 2022-12-07 | — | — | EP | disclosed |
| WO-2022247920-A1 | QUINOLINAMINE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN PHARMACEUTICALS | 江苏恒瑞医药股份有限公司 | 2022-12-01 | — | — | WO | disclosed |
| US-11512048-B2 | Heat sensitive recording material, and color developer | SOLENIS TECHNOLOGIES, L.P. (US) | 2022-11-29 | — | — | US | disclosed |
| US-20220365086-A1 | INHIBITORS OF OPLOPHORUS LUCIFERASE-DERIVED BIOLUMINESCENT COMPLEXES | PROMEGA CORPORATION | 2022-11-17 | — | — | US | disclosed |
| CN-115244059-A | Organic molecules for optoelectronic devices | 三星显示有限公司 | 2022-10-25 | — | — | CN | disclosed |
| US-11459302-B2 | Refining process and refining system of caprolactam | Zhejiang Hengyi Petrochemical Research Institute Co., Ltd. (CN) | 2022-10-04 | — | — | US | disclosed |
| CN-112142637-B | Method and system for refining caprolactam | 浙江恒逸石化研究院有限公司 | 2022-09-02 | — | — | CN | disclosed |
| CN-114920697-A | Heterocyclic group substituted indan propionamide compound and application thereof | 河南应用技术职业学院 | 2022-08-19 | — | — | CN | disclosed |
| EP-3802514-B1 | INHIBITORS OF OPLOPHORUS LUCIFERASE-DERIVED BIOLUMINESCENT COMPLEXES | PROMEGA CORP (US) | 2022-08-03 | — | — | EP | disclosed |
| CN-112601668-B | Thermosensitive recording material and color-developing agent | 索理思科技开曼公司 | 2022-07-29 | — | — | CN | disclosed |
| US-11390599-B2 | Inhibitors of oplophorus luciferase-derived bioluminescent complexes | PROMEGA CORPORATION (US) | 2022-07-19 | — | — | US | disclosed |
| US-11384055-B2 | Glycolate oxidase inhibitors for the treatment of disease | BIOMARIN PHARMACEUTICAL INC. (US) | 2022-07-12 | — | — | US | disclosed |
| WO-2022139513-A1 | COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME | 주식회사 엘지화학 | 2022-06-30 | — | — | WO | disclosed |
| EP-4016656-A1 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND DIAGNOSTIC COMPOSITION INCLUDING THE ORGANOMETALLIC COMPOUND | Samsung Electronics Co., Ltd. (KR) | 2022-06-22 | — | — | EP | disclosed |
| US-11358932-B2 | N-(1-hydroxy-3-(pyrrolidinyl)propan-2-yl)pyrrolidine-3-carboxamide derivatives as glucosylceramide synthase inhibitors | BIOMARIN PHARMACEUTICAL INC. (US) | 2022-06-14 | — | — | US | disclosed |
| EP-4002509-A1 | LIGHT-EMITTING DEVICE AND ELECTRONIC APPARATUS INCLUDING THE SAME | Samsung Electronics Co., Ltd. (KR) | 2022-05-25 | — | — | EP | disclosed |
| EP-3992199-A1 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE | Samsung Electronics Co., Ltd. (KR) | 2022-05-04 | — | — | EP | disclosed |
| EP-3992200-A1 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING ORGANOMETALLIC COMPOUND, AND DIAGNOSTIC COMPOSITION INCLUDING ORGANOMETALLIC COMPOUND | Samsung Electronics Co., Ltd. (KR) | 2022-05-04 | — | — | EP | disclosed |
| CN-110632207-B | Method for identifying mold based on volatile gas components and evolution trend thereof | 南京财经大学 | 2022-04-29 | — | — | CN | disclosed |
| US-11309493-B2 | Formulations with a low particle content | MERCK PATENT GMBH (DE) | 2022-04-19 | — | — | US | disclosed |
| WO-2022076735-A1 | INHIBITORS OF THE BROMODOMAIN PHD FINGER TRANSCRIPTION FACTOR (BPTF) AS ANTI-CANCER AGENTS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2022-04-14 | — | — | WO | disclosed |
| US-20220089545-A1 | REFINING PROCESS AND REFINING SYSTEM OF CAPROLACTAM | ZHEJIANG HENGLAN SCIENCE & TECHNOLOGY CO., LTD. (CN) | 2022-03-24 | — | — | US | disclosed |
| EP-3957701-A1 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE | Samsung Electronics Co., Ltd. (KR) | 2022-02-23 | — | — | EP | disclosed |
| US-20220047582-A1 | PHENYLPIPERAZINE PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) MODULATORS AND THEIR USE | SRX CARDIO, LLC | 2022-02-17 | — | — | US | disclosed |
| EP-3604321-B1 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND DIAGNOSTIC COMPOSITION INCLUDING THE ORGANOMETALLIC COMPOUND | SAMSUNG ELECTRONICS CO LTD (KR) | 2022-02-09 | — | — | EP | disclosed |
| EP-3943499-A2 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE | Samsung Electronics Co., Ltd. (KR) | 2022-01-26 | — | — | EP | disclosed |
| EP-3549944-B1 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND DIAGNOSTIC COMPOSITION INCLUDING THE ORGANOMETALLIC COMPOUND | SAMSUNG ELECTRONICS CO LTD (KR) | 2021-12-29 | — | — | EP | disclosed |
| US-11211557-B2 | Formulations with a low content of phenol type impurities | MERCK PATENT GMBH (DE) | 2021-12-28 | — | — | US | disclosed |
| EP-3426653-B1 | BICYCLIC COMPOUNDS FOR DIAGNOSIS AND THERAPY | AC IMMUNE SA (CH) | 2021-12-15 | — | — | EP | disclosed |
| EP-3617216-B1 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND DIAGNOSTIC COMPOSITION INCLUDING THE ORGANOMETALLIC COMPOUND | SAMSUNG ELECTRONICS CO LTD (KR) | 2021-12-01 | — | — | EP | disclosed |
| EP-3715437-B1 | COMPOSITION AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG ELECTRONICS CO LTD (KR) | 2021-12-01 | — | — | EP | disclosed |
| EP-3912983-A1 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING ORGANOMETALLIC COMPOUND, AND ELECTRONIC APPARATUS INCLUDING ORGANIC LIGHT-EMITTING DEVICE | Samsung Electronics Co., Ltd. (KR) | 2021-11-24 | — | — | EP | disclosed |
| EP-3909964-A2 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE | Samsung Electronics Co., Ltd. (KR) | 2021-11-17 | — | — | EP | disclosed |
| EP-3904363-A1 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE | Samsung Electronics Co., Ltd. (KR) | 2021-11-03 | — | — | EP | disclosed |
| EP-3674308-B1 | ORGANOMETALLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG ELECTRONICS CO LTD (KR) | 2021-11-03 | — | — | EP | disclosed |
| EP-3896073-A1 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING ORGANOMETALLIC COMPOUND, AND ELECTRONIC APPARATUS INCLUDING ORGANIC LIGHT-EMITTING DEVICE | Samsung Electronics Co., Ltd. (KR) | 2021-10-20 | — | — | EP | disclosed |
| US-11149011-B2 | Compounds and methods for IDO and TDO modulation, and indications therefor | PLEXXIKON INC. (US) | 2021-10-19 | — | — | US | disclosed |
| US-11149011-B2 | Compounds and methods for IDO and TDO modulation, and indications therefor | PLEXXIKON INC. (US) | 2021-10-19 | — | — | US | disclosed |
| US-20210292325-A1 | LIGANDS TO CEREBLON (CRBN) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-09-23 | — | — | US | disclosed |
| EP-3865553-A1 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE | Samsung Electronics Co., Ltd. (KR) | 2021-08-18 | — | — | EP | disclosed |
| EP-3862360-A1 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE | Samsung Electronics Co., Ltd. (KR) | 2021-08-11 | — | — | EP | disclosed |
| US-11084784-B2 | ROR-gamma modulators and uses thereof | Piramal Enterprises Limited (IN) | 2021-08-10 | — | — | US | disclosed |
| US-11084824-B2 | Pyrazolopyrimidine derivatives, preparation method thereof, and pharmaceutical composition for use in preventing or treating cancer, autoimmune disease and brain disease containing the same as an active ingredient | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2021-08-10 | — | — | US | disclosed |
| WO-2021151532-A1 | ORGANIC MOLECULES FOR OPTOELECTRONIC DEVICES | CYNORA GMBH (DE) | 2021-08-05 | — | — | WO | disclosed |
| EP-3851443-A1 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING ORGANOMETALLIC COMPOUND, AND ELECTRONIC APPARATUS INCLUDING ORGANIC LIGHT-EMITTING DEVICE | Samsung Electronics Co., Ltd. (KR) | 2021-07-21 | — | — | EP | disclosed |
| EP-3663308-B1 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE ORGANOMETALLIC COMPOUND, AND DIAGNOSTIC COMPOSITION INCLUDING THE ORGANOMETALLIC COMPOUND | SAMSUNG ELECTRONICS CO LTD (KR) | 2021-07-14 | — | — | EP | disclosed |
| EP-3842444-A1 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE | Samsung Electronics Co., Ltd. (KR) | 2021-06-30 | — | — | EP | disclosed |
| EP-3838908-A1 | ORGANOMETALLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | Samsung Electronics Co., Ltd. (KR) | 2021-06-23 | — | — | EP | disclosed |
| US-20210171474-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2021-06-10 | — | — | US | disclosed |
| WO-2021107681-A1 | COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | 주식회사 엘지화학 | 2021-06-03 | — | — | WO | disclosed |
| WO-2021107737-A1 | ORGANIC LIGHT-EMITTING ELEMENT | 주식회사 엘지화학 | 2021-06-03 | — | — | WO | disclosed |
| WO-2021107736-A1 | ORGANIC LIGHT-EMITTING ELEMENT | 주식회사 엘지화학 | 2021-06-03 | — | — | WO | disclosed |
| EP-3828190-A1 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE ORGANOMETALLIC COMPOUND AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE | Samsung Electronics Co., Ltd. (KR) | 2021-06-02 | — | — | EP | disclosed |
| EP-3828174-A1 | PYRIDAZINONE DERIVATIVE | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2021-06-02 | — | — | EP | disclosed |
| EP-3825320-A1 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING ORGANOMETALLIC COMPOUND, AND DIAGNOSTIC COMPOSITION INCLUDING ORGANOMETALLIC COMPOUND | Samsung Electronics Co., Ltd. (KR) | 2021-05-26 | — | — | EP | disclosed |
| US-20210151679-A1 | FORMULATIONS WITH A LOW CONTENT OF PHENOL TYPE IMPURITIES | MERCK PATENT GMBH (DE) | 2021-05-20 | — | — | US | disclosed |
| EP-3813829-A1 | LIGANDS TO CEREBLON (CRBN) | Dana Farber Cancer Institute, Inc. (US) | 2021-05-05 | — | — | EP | disclosed |
| US-20210119129-A1 | FORMULATIONS WITH A LOW PARTICLE CONTENT | MERCK PATENT GMBH (DE) | 2021-04-22 | — | — | US | disclosed |
| US-10980801-B2 | Phenylpiperazine proprotein convertase subtilisin/kexin type 9 (PCSK9) modulators and their use | SRX CARDIO, LLC (US) | 2021-04-20 | — | — | US | disclosed |
| EP-3802514-A1 | INHIBITORS OF OPLOPHORUS LUCIFERASE-DERIVED BIOLUMINESCENT COMPLEXES | Promega Corporation (US) | 2021-04-14 | — | — | EP | disclosed |
| CN-112638380-A | Cereblon (CRBN) ligands | 达纳-法伯癌症研究所有限公司 | 2021-04-09 | — | — | CN | disclosed |
| CN-110407229-B | Method for synthesizing CHA structure molecular sieve and CHA structure molecular sieve | 中国石油化工股份有限公司 | 2021-04-06 | — | — | CN | disclosed |
| CN-110407230-B | Method for synthesizing CHA structure molecular sieve and CHA structure molecular sieve | 中国石油化工股份有限公司 | 2021-04-06 | — | — | CN | disclosed |
| CN-110407231-B | Method for synthesizing copper-containing CHA structure molecular sieve and copper-containing CHA structure molecular sieve | 中国石油化工股份有限公司 | 2021-04-06 | — | — | CN | disclosed |
| CN-112601668-A | Thermosensitive recording material and color-developing agent | 索理思科技开曼公司 | 2021-04-02 | — | — | CN | disclosed |
| WO-2021061929-A1 | BICYCLIC CARBOXYLATES AS MODULATORS OF TRANSPORTERS AND USES THEREOF | Nirogy Therapeutics, Inc. (US) | 2021-04-01 | — | — | WO | disclosed |
| WO-2021049889-A1 | COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | 주식회사 엘지화학 | 2021-03-18 | — | — | WO | disclosed |
| WO-2021050721-A1 | QUINOLINE DERIVATIVES AND USES IN MANAGING CANCER | EMORY UNIVERSITY (US) | 2021-03-18 | — | — | WO | disclosed |
| WO-2021050721-A1 | QUINOLINE DERIVATIVES AND USES IN MANAGING CANCER | EMORY UNIVERSITY (US) | 2021-03-18 | — | — | WO | disclosed |
| US-10916705-B2 | Formulations with a low particle content | MERCK PATENT GMBH (DE) | 2021-02-09 | — | — | US | disclosed |
| WO-2021020928-A2 | POLYCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING ELEMENT COMPRISING SAME | 주식회사 엘지화학 | 2021-02-04 | — | — | WO | disclosed |
| US-20210032214-A1 | COMPOUNDS FOR BINDING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 | SRX CARDIO, LLC | 2021-02-04 | — | — | US | disclosed |
| EP-3768666-A1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION, AND INDICATIONS THEREFOR | Plexxikon Inc. (US) | 2021-01-27 | — | — | EP | disclosed |
| US-20210002215-A1 | HEAT SENSITIVE RECORDING MATERIAL AND COLOR DEVELOPER | SOLENIS TECHNOLOGIES CAYMAN, L.P. (KY) | 2021-01-07 | — | — | US | disclosed |
| EP-3758947-A1 | HEAT SENSITIVE RECORDING MATERIAL AND COLOR DEVELOPER | Solenis Technologies Cayman, L.P. (KY) | 2021-01-06 | — | — | EP | disclosed |
| EP-3761385-A1 | COMPOSITION AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | Samsung Electronics Co., Ltd. (KR) | 2021-01-06 | — | — | EP | disclosed |
| CN-112159357-A | Refining method of caprolactam | 浙江恒澜科技有限公司 | 2021-01-01 | — | — | CN | disclosed |
| CN-112142637-A | Method and system for refining caprolactam | 浙江恒澜科技有限公司 | 2020-12-29 | — | — | CN | disclosed |
| WO-2020257487-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2020-12-24 | — | — | WO | disclosed |
| CN-112119072-A | Compounds and methods for IDO and TDO modulation, and indications thereof | 普莱希科公司 | 2020-12-22 | — | — | CN | disclosed |
| WO-2020252205-A1 | INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY | Praxis Biotech LLC (US) | 2020-12-17 | — | — | WO | disclosed |
| CN-112079760-A | Method and system for refining caprolactam | 浙江恒澜科技有限公司 | 2020-12-15 | — | — | CN | disclosed |
| CN-107635963-B | Guanidine compounds and uses thereof | 伊谬诺米特医疗有限公司 | 2020-11-20 | — | — | CN | disclosed |
| US-10822352-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2020-11-03 | — | — | US | disclosed |
| EP-3539951-B1 | NOVEL PYRIMIDINE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING CANCER AND INFLAMMATORY DISEASES | KOREA RES INST CHEMICAL TECH (KR) | 2020-10-07 | — | — | EP | disclosed |
| EP-3715355-A1 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE | Samsung Electronics Co., Ltd. (KR) | 2020-09-30 | — | — | EP | disclosed |
| EP-3705477-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | Vertex Pharmaceuticals Incorporated (US) | 2020-09-09 | — | — | EP | disclosed |
| US-20200277255-A1 | BIGUANIDE COMPOUND AND USE THEREOF | IMMUNOMET THERAPEUTICS INC. | 2020-09-03 | — | — | US | disclosed |
| US-20200253958-A1 | PHENYLPIPERAZINE PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) MODULATORS AND THEIR USE | SRX CARDIO, LLC | 2020-08-13 | — | — | US | disclosed |
| EP-3689888-A1 | ORGANOMETALLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | Samsung Electronics Co., Ltd. (KR) | 2020-08-05 | — | — | EP | disclosed |
| US-10734587-B2 | Formulations of luminescent compounds | MERCK PATENT GMBH (DE) | 2020-08-04 | — | — | US | disclosed |
| EP-3222614-B1 | BIGUANIDE COMPOUND AND USE THEREOF | IMMUNOMET THERAPEUTICS INC (US) | 2020-07-29 | — | — | EP | disclosed |
| US-10696611-B2 | Adamantane derivative compound | AMOREPACIFIC CORPORATION (KR) | 2020-06-30 | — | — | US | disclosed |
| US-20200199129-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR USE IN PREVENTING OR TREATING CANCER, AUTOIMMUNE DISEASE AND BRAIN DISEASE CONTAINING THE SAME AS AN ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2020-06-25 | — | — | US | disclosed |
| CN-110114344-B | Novel pyrimidine compound, method for preparing same, and pharmaceutical composition containing same as active ingredient for preventing or treating cancer and inflammatory disease | 韩国化学研究院 | 2020-06-16 | — | — | CN | disclosed |
| US-20200172534-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2020-06-04 | — | — | US | disclosed |
| US-10662192-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-05-26 | — | — | US | disclosed |
| US-10647686-B2 | Substituted pyrimidines for preventing or treating cancer and inflammatory diseases | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2020-05-12 | — | — | US | disclosed |
| US-10626085-B2 | Biguanide compound and use thereof | IMMUNOMET THERAPEUTICS INC. (US) | 2020-04-21 | — | — | US | disclosed |
| EP-3637489-A1 | ORGANOMETALLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | Samsung Electronics Co., Ltd. (KR) | 2020-04-15 | — | — | EP | disclosed |
| EP-3617215-A1 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE ORGANOMETALLIC COMPOUND, AND DIAGNOSTIC COMPOSITION INCLUDING THE ORGANOMETALLIC COMPOUND | Samsung Electronics Co., Ltd. (KR) | 2020-03-04 | — | — | EP | disclosed |
| US-10568882-B2 | Phenylpiperazine proprotein convertase subtilisin/kexin type 9 (PCSK9) modulators and their use | SRX CARDIO, LLC (US) | 2020-02-25 | — | — | US | disclosed |
| US-10570156-B2 | Substituted imidazo[1,2-a]pyridines as PDE-10 inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2020-02-25 | — | — | US | disclosed |
| US-10570156-B2 | Substituted imidazo[1,2-a]pyridines as PDE-10 inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2020-02-25 | — | — | US | disclosed |
| EP-3216787-B1 | INTERMEDIATES FOR THE PREPARATION OF MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMA (US) | 2020-02-19 | — | — | EP | disclosed |
| CN-107207416-B | Novel adamantane derivative compound | 株式会社爱茉莉太平洋 | 2020-02-07 | — | — | CN | disclosed |
| EP-3604321-A1 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND DIAGNOSTIC COMPOSITION INCLUDING THE ORGANOMETALLIC COMPOUND | Samsung Electronics Co., Ltd. (KR) | 2020-02-05 | — | — | EP | disclosed |
| CN-110632207-A | Method for identifying mold based on volatile gas components and evolution trend thereof | 南京财经大学 | 2019-12-31 | — | — | CN | disclosed |
| EP-3230403-B1 | ORGANIC COMPOUNDS WITH SOLUBLE GROUPS | MERCK PATENT GMBH (DE) | 2019-10-09 | — | — | EP | disclosed |
| US-20190300487-A1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2019-10-03 | — | — | US | disclosed |
| US-20190300487-A1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2019-10-03 | — | — | US | disclosed |
| WO-2019183145-A1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2019-09-26 | — | — | WO | disclosed |
| WO-2019183145-A1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2019-09-26 | — | — | WO | disclosed |
| US-20190284143-A1 | NOVEL PYRIMIDINE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING CANCER AND INFLAMMATORY DISEASES | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2019-09-19 | — | — | US | disclosed |
| EP-3539951-A1 | NOVEL PYRIMIDINE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING CANCER AND INFLAMMATORY DISEASES | Korea Research Institute of Chemical Technology (KR) | 2019-09-18 | — | — | EP | disclosed |
| US-20190276398-A1 | N-(1-HYDROXY-3-(PYRROLIDINYL)PROPAN-2-YL)PYRROLIDINE-3-CARBOXAMIDE DERIVATIVES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | BIOMARIN PHARM INC (US) | 2019-09-12 | — | — | US | disclosed |
| EP-3533619-A1 | HEAT SENSITIVE RECORDING MATERIAL AND COLOR DEVELOPER | BASF SE (DE) | 2019-09-04 | — | — | EP | disclosed |
| CN-110114344-A | New pyrimidine compound and preparation method thereof, and contain pharmaceutical composition of the compound as prevention or treating cancer and the active constituent of diseases associated with inflammation | 韩国化学研究院 | 2019-08-09 | — | — | CN | disclosed |
| EP-3515892-A1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION, AND INDICATIONS THEREFOR | Plexxikon Inc. (US) | 2019-07-31 | — | — | EP | disclosed |
| US-20190211033-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2019-07-11 | — | — | US | disclosed |
| EP-3116973-B1 | FORMULATIONS OF LUMINESCENT COMPOUNDS | MERCK PATENT GMBH (DE) | 2019-06-19 | — | — | EP | disclosed |
| EP-3210984-B1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC (US) | 2019-06-19 | — | — | EP | disclosed |
| EP-3210984-B1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC (US) | 2019-06-19 | — | — | EP | disclosed |
| EP-2558446-B1 | NOVEL COMPOUNDS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS | AC IMMUNE SA (CH) | 2019-06-12 | — | — | EP | disclosed |
| US-20190144450-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-05-16 | — | — | US | disclosed |
| US-20190144464-A1 | BIGUANIDE COMPOUNDS AND USE THEREOF | HANALL BIOPHARMA CO., LTD. (KR) | 2019-05-16 | — | — | US | disclosed |
| US-10287301-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2019-05-14 | — | — | US | disclosed |
| US-20190119236-A1 | COMPOUNDS FOR BINDING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | SRX CARDIO, LLC | 2019-04-25 | — | — | US | disclosed |
| US-20190119236-A1 | COMPOUNDS FOR BINDING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | SRX CARDIO, LLC | 2019-04-25 | — | — | US | disclosed |
| EP-3091019-B1 | PURINE DERIVATIVES USEFUL AS HSP90 INHIBITORS | SLOAN KETTERING INST CANCER RES (US) | 2019-04-03 | — | — | EP | disclosed |
| US-10239832-B2 | N-(1-hydroxy-3-(pyrrolidinyl)propan-2-yl)pyrrolidine-3-carboxamide derivatives as glucosylceramide synthase inhibitors | BIOMARIN PHARMACEUTICAL INC. (US) | 2019-03-26 | — | — | US | disclosed |
| US-10221190-B2 | Biguanide compounds and use thereof | IMMUNOMET THERAPEUTICS INC. (US) | 2019-03-05 | — | — | US | disclosed |
| US-10172863-B2 | Purine derivatives useful as HSP90 inhibitors | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2019-01-08 | — | — | US | disclosed |
| WO-2018208132-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR USE IN PREVENTING OR TREATING CANCER, AUTOIMMUNE DISEASE AND BRAIN DISEASE CONTAINING THE SAME AS AN ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2018-11-15 | — | — | WO | disclosed |
| US-20180250291-A1 | COMPOSITION AND METHODS OF USE OF NOVEL PHENYLALANINE SMALL ORGANIC COMPOUNDS TO DIRECTLY MODULATE PCSK9 PROTEIN ACTIVITY | SRX CARDIO, LLC | 2018-09-06 | — | — | US | disclosed |
| US-20180215707-A1 | ROR-GAMMA MODULATORS AND USES THEREOF | Piramal Enterprises Limited (IN) | 2018-08-02 | — | — | US | disclosed |
| EP-3077475-B1 | COMPOSITIONS CONTAINING A POLYMERIC BINDER WHICH COMPRISES ACRYLIC AND/OR METHACRYLIC ACID ESTER UNITS | MERCK PATENT GMBH (DE) | 2018-07-04 | — | — | EP | disclosed |
| US-10011612-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2018-07-03 | — | — | US | disclosed |
| EP-3337788-A1 | PHENYLPIPERAZINE PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) MODULATORS AND THEIR USE | Portola Pharmaceuticals, Inc. (US) | 2018-06-27 | — | — | EP | disclosed |
| EP-2970106-B1 | BORON-CONTAINING DIACYLHYDRAZINES | INTREXON CORP (US) | 2018-05-16 | — | — | EP | disclosed |
| US-20180123054-A1 | COMPOSITION FOR ORGANIC ELECTROLUMINESCENT ELEMENT, ORGANIC ELECTROLUMINESCENT ELEMENT, DISPLAY AND LIGHTING | MITSUBISHI CHEMICAL CORPORATION (JP) | 2018-05-03 | — | — | US | disclosed |
| US-20180099939-A1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2018-04-12 | — | — | US | disclosed |
| US-20180099939-A1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2018-04-12 | — | — | US | disclosed |
| US-20180099939-A1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2018-04-12 | — | — | US | disclosed |
| WO-2018057973-A1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2018-03-29 | — | — | WO | disclosed |
| WO-2018057973-A1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2018-03-29 | — | — | WO | disclosed |
| US-20180072759-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2018-03-15 | — | — | US | disclosed |
| US-20180072759-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2018-03-15 | — | — | US | disclosed |
| US-20180072759-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2018-03-15 | — | — | US | disclosed |
| EP-3063141-B1 | N-(1-HYDROXY-3-(PYRROLIDINYL)PROPAN-2-YL)PYRROLIDINE-3-CARBOXAMIDE DERIVATIVES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | BIOMARIN PHARM INC (US) | 2018-02-28 | — | — | EP | disclosed |
| US-9899606-B2 | Composition for organic electroluminescent element, organic electroluminescent element, display and lighting | MITSUBISHI CHEMICAL CORPORATION (JP) | 2018-02-20 | — | — | US | disclosed |
| US-9899606-B2 | Composition for organic electroluminescent element, organic electroluminescent element, display and lighting | MITSUBISHI CHEMICAL CORPORATION (JP) | 2018-02-20 | — | — | US | disclosed |
| US-20180044283-A1 | BIGUANIDE COMPOUND AND USE THEREOF | IMMUNOMET THERAPEUTICS INC. (US) | 2018-02-15 | — | — | US | disclosed |
| US-20180030005-A1 | TETRAHYDRONAPHTHYRIDINE, BENZOXAZINE, AZA-BENZOXAZINE AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE | MERCK SHARP & DOHME LLC | 2018-02-01 | — | — | US | disclosed |
| US-20180013067-A1 | FORMULATIONS WITH A LOW PARTICLE CONTENT | MERCK PATENT GMBH (DE) | 2018-01-11 | — | — | US | disclosed |
| US-9856274-B2 | Substituted pyrazolo[1,5-a]pyridines as PDE-10 inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2018-01-02 | — | — | US | disclosed |
| US-9856274-B2 | Substituted pyrazolo[1,5-a]pyridines as PDE-10 inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2018-01-02 | — | — | US | disclosed |
| US-20170362508-A1 | POLYMERIZABLE COMPOUND AND OPTICALLY ANISOTROPIC BODY | DIC CORPORATION (JP) | 2017-12-21 | — | — | US | disclosed |
| US-20170362508-A1 | POLYMERIZABLE COMPOUND AND OPTICALLY ANISOTROPIC BODY | DIC CORPORATION (JP) | 2017-12-21 | — | — | US | disclosed |
| EP-3251128-A1 | FORMULATIONS WITH A LOW PARTICLE CONTENT | Merck Patent GmbH (DE) | 2017-12-06 | — | — | EP | disclosed |
| WO-2017192931-A1 | SUBSTITUTED IMDAZO[1,2-α]PYRIDINES, SUBSTITUTED IMIDAZO[1,2-α]PYRAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | LYSOSOMAL THERAPEUTICS INC. (US) | 2017-11-09 | — | — | WO | disclosed |
| WO-2017192929-A1 | SUBSTITUTED PYRROLO[1,2-α]TRIAZINES AND RELATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | LYSOSOMAL THERAPEUTICS INC. (US) | 2017-11-09 | — | — | WO | disclosed |
| WO-2017192841-A1 | METHODS OF TREATMENT AND COMBINATION THERAPIES USING GCASE ACTIVATOR HETEROBICYCLIC AND RELATED COMPOUNDS | LYSOSOMAL THERAPEUTICS INC. (US) | 2017-11-09 | — | — | WO | disclosed |
| WO-2017192930-A1 | SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | LYSOSOMAL THERAPEUTICS INC. (US) | 2017-11-09 | — | — | WO | disclosed |
| US-9809561-B2 | Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease | MERCK SHARP & DOHME CORP. (US) | 2017-11-07 | — | — | US | disclosed |
| EP-2940000-B1 | PROCESS FOR PREPARING METHYL ACETATE | DALIAN INST CHEMICAL PHYSICS CAS (CN) | 2017-10-18 | — | — | EP | disclosed |
| WO-2017176961-A1 | IMIDAZO [1,5-A]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | LYSOSOMAL THERAPEUTICS INC. (US) | 2017-10-12 | — | — | WO | disclosed |
| WO-2017176960-A1 | PYRAZOLO[1,5-A]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | LYSOSOMAL THERAPEUTICS INC. (US) | 2017-10-12 | — | — | WO | disclosed |
| WO-2017176962-A1 | PYRROLO[1,2-A]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | LYSOSOMAL THERAPEUTICS, INC. (US) | 2017-10-12 | — | — | WO | disclosed |
| US-20170283347-A1 | NOVEL ADAMANTANE DERIVATIVE COMPOUND | AMOREPACIFIC CORPORATION (KR) | 2017-10-05 | — | — | US | disclosed |
| EP-3222614-A2 | BIGUANIDE COMPOUND AND USE THEREOF | Immunomet Therapeutics Inc. (US) | 2017-09-27 | — | — | EP | disclosed |
| WO-2017161137-A1 | METHODS AND COMPOSITIONS FOR TREATING A NEURODEGENERATIVE DISORDER IN A SPHINGOTYPED SUBJECT | LYSOSOMAL THERAPEUTICS INC. (US) | 2017-09-21 | — | — | WO | disclosed |
| EP-3216787-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | Vertex Pharmaceuticals Incorporated (US) | 2017-09-13 | — | — | EP | disclosed |
| WO-2017147328-A1 | COMPOUNDS FOR BINDING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | PORTOLA PHARMACEUTICALS, INC. (US) | 2017-08-31 | — | — | WO | disclosed |
| WO-2017147328-A1 | COMPOUNDS FOR BINDING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | PORTOLA PHARMACEUTICALS, INC. (US) | 2017-08-31 | — | — | WO | disclosed |
| EP-3210984-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | Sunovion Pharmaceuticals Inc. (US) | 2017-08-30 | — | — | EP | disclosed |
| EP-3210984-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | Sunovion Pharmaceuticals Inc. (US) | 2017-08-30 | — | — | EP | disclosed |
| EP-3187486-A1 | NOVEL ADAMANTANE DERIVATIVE COMPOUND | Amorepacific Corporation (KR) | 2017-07-05 | — | — | EP | disclosed |
| US-20170152213-A1 | AMINE-CONTAINING LIPIDOIDS AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2017-06-01 | — | — | US | disclosed |
| EP-2517274-B1 | COMPOSITIONS COMPRISING POLYMERIC BINDERS | MERCK PATENT GMBH (DE) | 2017-05-24 | — | — | EP | disclosed |
| EP-2502911-B1 | Modulators of ATP-binding cassette transporters | VERTEX PHARMA (US) | 2017-04-05 | — | — | EP | disclosed |
| US-20170084844-A1 | FORMULATIONS OF LUMINESCENT COMPOUNDS | MERCK PATENT GMBH (DE) | 2017-03-23 | — | — | US | disclosed |
| EP-2663565-B1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC (US) | 2017-03-15 | — | — | EP | disclosed |
| EP-2663565-B1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC (US) | 2017-03-15 | — | — | EP | disclosed |
| US-20170066783-A1 | Aryl, Heteroaryl, and Heterocyclic Compounds for Treatment of Medical Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-09 | — | — | US | disclosed |
| US-20170066783-A1 | Aryl, Heteroaryl, and Heterocyclic Compounds for Treatment of Medical Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-09 | — | — | US | disclosed |
| WO-2017040877-A1 | HETEROBICYCLIC PYRIMIDINONE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | LYSOSOMAL THERAPEUTICS INC. (US) | 2017-03-09 | — | — | WO | disclosed |
| WO-2017034997-A1 | PHENYLPIPERAZINE PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) MODULATORS AND THEIR USE | PORTOLA PHARMACEUTICALS, INC. (US) | 2017-03-02 | — | — | WO | disclosed |
| EP-3122721-A1 | ROR-GAMMA MODULATORS AND USES THEREOF | Piramal Enterprises Limited (IN) | 2017-02-01 | — | — | EP | disclosed |
| US-9556311-B2 | Polyimide precursor composition, article prepared by using same, and display device including the article | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2017-01-31 | — | — | US | disclosed |
| EP-1978533-B1 | CAPACITOR AND METHOD FOR MANUFACTURING SAME | SHOWA DENKO KK (JP) | 2016-11-16 | — | — | EP | disclosed |
| EP-3091019-A2 | PURINE DERIVATIVES USEFUL AS HSP90 INHIBITORS | Sloan Kettering Institute For Cancer Research (US) | 2016-11-09 | — | — | EP | disclosed |
| US-20160318931-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-11-03 | — | — | US | disclosed |
| US-20160310497-A1 | PURINE DERIVATIVES USEFUL AS HSP90 INHIBITORS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2016-10-27 | — | — | US | disclosed |
| US-20160310497-A1 | PURINE DERIVATIVES USEFUL AS HSP90 INHIBITORS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2016-10-27 | — | — | US | disclosed |
| EP-2725632-B1 | USE OF COMPOSITIONS COMPRISING POLYMERIC INERT BINDERS FOR THE FABRICAITON OF LIGHT-EMITTING DIODE | MERCK PATENT GMBH (DE) | 2016-10-26 | — | — | EP | disclosed |
| US-20160304476-A1 | TETRAHYDRONAPHTHYRIDINE, BENZOXAZINE, AZA-BENZOXAZINE AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE | MERCK SHARP & DOHME LLC | 2016-10-20 | — | — | US | disclosed |
| US-20160301003-A1 | COMPOSITIONS CONTAINING A POLYMERIC BINDER WHICH COMPRISES ACRYLIC AND/OR METHACRYLIC ACID ESTER UNITS | MERCK PATENT GMBH (DE) | 2016-10-13 | — | — | US | disclosed |
| US-20160280643-A1 | N-(1-HYDROXY-3-(PYRROLIDINYL)PROPAN-2-YL)PYRROLIDINE-3-CARBOXAMIDE DERIVATIVES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | BIOMARIN PHARMACEUTICAL INC. | 2016-09-29 | — | — | US | disclosed |
| US-20160280643-A1 | N-(1-HYDROXY-3-(PYRROLIDINYL)PROPAN-2-YL)PYRROLIDINE-3-CARBOXAMIDE DERIVATIVES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | BIOMARIN PHARMACEUTICAL INC. | 2016-09-29 | — | — | US | disclosed |
| US-9440226-B2 | Method for preparing methyl acetate | DALIAN INSTITUTE OF CHEMICAL PHYSICS, CHINESE ACADEMY OF SCIENCES (CN) | 2016-09-13 | — | — | US | disclosed |
| WO-2016120007-A1 | FORMULATIONS WITH A LOW PARTICLE CONTENT | MERCK PATENT GMBH (DE) | 2016-08-04 | — | — | WO | disclosed |
| EP-2486039-B1 | PURINE DERIVATIVES USEFUL AS HSP90 INHIBITORS | SLOAN KETTERING INST CANCER (US) | 2016-06-01 | — | — | EP | disclosed |
| EP-2681221-B1 | TRICYCLIC INHIBITORS OF KINASES | ABBVIE INC (US) | 2016-05-18 | — | — | EP | disclosed |
| US-9328114-B2 | Hsp90 inhibitors | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2016-05-03 | — | — | US | disclosed |
| US-9328114-B2 | Hsp90 inhibitors | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2016-05-03 | — | — | US | disclosed |
| US-20160102106-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2016-04-14 | — | — | US | disclosed |
| US-20160102106-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2016-04-14 | — | — | US | disclosed |
| US-20160102106-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2016-04-14 | — | — | US | disclosed |
| US-9293713-B2 | Arylamine compound | RICOH COMPANY, LTD. (JP) | 2016-03-22 | — | — | US | disclosed |
| US-9293713-B2 | Arylamine compound | RICOH COMPANY, LTD. (JP) | 2016-03-22 | — | — | US | disclosed |
| US-9293713-B2 | Arylamine compound | RICOH COMPANY, LTD. (JP) | 2016-03-22 | — | — | US | disclosed |
| US-20160043325-A1 | COMPOSITION FOR ORGANIC ELECTROLUMINESCENT ELEMENT, ORGANIC ELECTROLUMINESCENT ELEMENT, DISPLAY AND LIGHTING | MITSUBISHI CHEMICAL CORPORATION (JP) | 2016-02-11 | — | — | US | disclosed |
| US-20160043325-A1 | COMPOSITION FOR ORGANIC ELECTROLUMINESCENT ELEMENT, ORGANIC ELECTROLUMINESCENT ELEMENT, DISPLAY AND LIGHTING | MITSUBISHI CHEMICAL CORPORATION (JP) | 2016-02-11 | — | — | US | disclosed |
| US-9249162-B2 | Substituted [1,2,4]triazolo[1,5-a]pyridines as PDE-10 inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2016-02-02 | — | — | US | disclosed |
| US-9249162-B2 | Substituted [1,2,4]triazolo[1,5-a]pyridines as PDE-10 inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2016-02-02 | — | — | US | disclosed |
| US-9249162-B2 | Substituted [1,2,4]triazolo[1,5-a]pyridines as PDE-10 inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2016-02-02 | — | — | US | disclosed |
| US-9224959-B2 | Method for producing a pi-electron conjugated compound | RICOH COMPANY, LTD. (JP) | 2015-12-29 | — | — | US | disclosed |
| US-9224959-B2 | Method for producing a pi-electron conjugated compound | RICOH COMPANY, LTD. (JP) | 2015-12-29 | — | — | US | disclosed |
| US-20150336965-A1 | NOVEL ANTIVIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2015-11-26 | — | — | US | disclosed |
| US-20150336965-A1 | NOVEL ANTIVIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2015-11-26 | — | — | US | disclosed |
| US-20150336965-A1 | NOVEL ANTIVIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2015-11-26 | — | — | US | disclosed |
| US-20150315186-A2 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED | 2015-11-05 | — | — | US | disclosed |
| EP-2940000-A1 | PROCESS FOR PREPARING METHYL ACETATE | Dalian Institute Of Chemical Physics, Chinese Academy of Sciences (CN) | 2015-11-04 | — | — | EP | disclosed |
| US-9178156-B2 | Compositions comprising polymeric binders | MERCK PATENT GMBH (DE) | 2015-11-03 | — | — | US | disclosed |
| US-20150298108-A1 | METHOD FOR PREPARING METHYL ACETATE | DALIAN INSTITUTE OF CHEMICAL PHYSICS, CHINESE ACADEMY OF SCIENCES (CN) | 2015-10-22 | — | — | US | disclosed |
| US-20150293078-A1 | COMPOUNDS USEFUL IN CFTR ASSAYS AND METHODS THEREWITH | VERTEX PHARMACEUTICALS INCORPORATED | 2015-10-15 | — | — | US | disclosed |
| WO-2015145371-A1 | ROR-GAMMA MODULATORS AND USES THEREOF | Piramal Enterprises Limited (IN) | 2015-10-01 | — | — | WO | disclosed |
| US-9132129-B2 | Antiviral compounds | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2015-09-15 | — | — | US | disclosed |
| US-9132129-B2 | Antiviral compounds | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2015-09-15 | — | — | US | disclosed |
| US-9132129-B2 | Antiviral compounds | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2015-09-15 | — | — | US | disclosed |
| US-9123896-B2 | Organic electronic device containing an organic semiconductor material film which contains a leaving substituent-containing compound | RICOH COMPANY, LTD. (JP) | 2015-09-01 | — | — | US | disclosed |
| US-9123896-B2 | Organic electronic device containing an organic semiconductor material film which contains a leaving substituent-containing compound | RICOH COMPANY, LTD. (JP) | 2015-09-01 | — | — | US | disclosed |
| US-9120762-B2 | Salts of bicyclo-substituted pyrazolon azo derivatives, preparation method and use thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2015-09-01 | — | — | US | disclosed |
| US-9120762-B2 | Salts of bicyclo-substituted pyrazolon azo derivatives, preparation method and use thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2015-09-01 | — | — | US | disclosed |
| US-9120762-B2 | Salts of bicyclo-substituted pyrazolon azo derivatives, preparation method and use thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2015-09-01 | — | — | US | disclosed |
| US-20150231142-A1 | Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases | VERTEX PHARMA (US) | 2015-08-20 | — | — | US | disclosed |
| US-9090619-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-07-28 | — | — | US | disclosed |
| EP-2396316-B1 | QUINAZOLINONES AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-07-01 | — | — | EP | disclosed |
| US-9062221-B2 | Polymer, ink and organic film | RICOH COMPANY, LTD. (JP) | 2015-06-23 | — | — | US | disclosed |
| US-9062221-B2 | Polymer, ink and organic film | RICOH COMPANY, LTD. (JP) | 2015-06-23 | — | — | US | disclosed |
| US-20150150879-A2 | Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases | VERTEX PHARMACEUTICALS INCORPORATED | 2015-06-04 | — | — | US | disclosed |
| US-20150126518-A1 | BIGUANIDE COMPOUNDS AND USE THEREOF | HANALL BIOPHARMA CO., LTD. (KR) | 2015-05-07 | — | — | US | disclosed |
| WO-2015065937-A1 | N-(1-HYDROXY-3-(PYRROLIDINYL)PROPAN-2-YL)PYRROLIDINE-3-CARBOXAMIDE DERIVATIVES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | BIOMARIN PHARMACEUTICAL INC. (US) | 2015-05-07 | — | — | WO | disclosed |
| US-8987242-B2 | Morpholinone compounds as factor IXA inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-03-24 | — | — | US | disclosed |
| US-20150065487-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMA (US) | 2015-03-05 | — | — | US | disclosed |
| US-8969552-B2 | Arylsulfonylmethyl or arylsulfonamide substituted aromatic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-03-03 | — | — | US | disclosed |
| US-8952031-B2 | Amino- and amido-aminotetralin derivatives and related compounds as mu opioid receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-02-10 | — | — | US | disclosed |
| US-20150031722-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED | 2015-01-29 | — | — | US | disclosed |
| US-8937078-B2 | Quinazolinones as prolyl hydroxylase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2015-01-20 | — | — | US | disclosed |
| EP-2236500-B1 | BICYCLO-SUBSTITUTED PYRAZOLON AZO DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF | JIANGSU HENGRUI MEDICINE CO (CN) | 2014-12-24 | — | — | EP | disclosed |
| EP-2236500-B1 | BICYCLO-SUBSTITUTED PYRAZOLON AZO DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF | JIANGSU HENGRUI MEDICINE CO (CN) | 2014-12-24 | — | — | EP | disclosed |
| US-20140343098-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-11-20 | — | — | US | disclosed |
| US-20140343315-A1 | Modulators of ATP-Binding Cassette Transporters | VERTEX PHARMACEUTICALS INCORPORATED | 2014-11-20 | — | — | US | disclosed |
| EP-2439203-B1 | Arylsulfonylmethyl or arylsulfonamide substituted aromatic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor | ABBVIE DEUTSCHLAND (DE) | 2014-11-19 | — | — | EP | disclosed |
| US-20140329814-A2 | Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases | VERTEX PHARMA (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140288062-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2014-09-25 | — | — | US | disclosed |
| US-20140288062-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2014-09-25 | — | — | US | disclosed |
| US-20140288062-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2014-09-25 | — | — | US | disclosed |
| US-8829204-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-09-09 | — | — | US | disclosed |
| US-20140243335-A1 | SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-8802700-B2 | Modulators of ATP-Binding Cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-12 | — | — | US | disclosed |
| US-20140187797-A1 | LEAVING SUBSTITUENT-CONTAINING COMPOUND, ORGANIC SEMICONDUCTOR MATERIAL, ORGANIC SEMICONDUCTOR FILM CONTAINING THE MATERIAL, ORGANIC ELECTRONIC DEVICE CONTAINING THE FILM, METHOD FOR PRODUCING FILM-LIKE PRODUCT, PI-ELECTRON CONJUGATED COMPOUND AND METHOD FOR PRODUCING THE PI-ELECTRON CONJUGATED COMPOUND | GOTO DAISUKE (JP) | 2014-07-03 | — | — | US | disclosed |
| US-20140187770-A9 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-07-03 | — | — | US | disclosed |
| US-20140187797-A1 | LEAVING SUBSTITUENT-CONTAINING COMPOUND, ORGANIC SEMICONDUCTOR MATERIAL, ORGANIC SEMICONDUCTOR FILM CONTAINING THE MATERIAL, ORGANIC ELECTRONIC DEVICE CONTAINING THE FILM, METHOD FOR PRODUCING FILM-LIKE PRODUCT, PI-ELECTRON CONJUGATED COMPOUND AND METHOD FOR PRODUCING THE PI-ELECTRON CONJUGATED COMPOUND | GOTO DAISUKE (JP) | 2014-07-03 | — | — | US | disclosed |
| US-8765760-B2 | [1,2,4] triazol [1,5-a] pyrazines useful as inhibitors of phosphodiesterases | SUNOVION PHARMACEUTICALS, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-8765760-B2 | [1,2,4] triazol [1,5-a] pyrazines useful as inhibitors of phosphodiesterases | SUNOVION PHARMACEUTICALS, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-8765760-B2 | [1,2,4] triazol [1,5-a] pyrazines useful as inhibitors of phosphodiesterases | SUNOVION PHARMACEUTICALS, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-20140175416-A1 | LEAVING SUBSTITUENT-CONTAINING COMPOUND, ORGANIC SEMICONDUCTOR MATERIAL, ORGANIC SEMICONDUCTOR FILM CONTAINING THE MATERIAL, ORGANIC ELECTRONIC DEVICE CONTAINING THE FILM, METHOD FOR PRODUCING FILM-LIKE PRODUCT, PI-ELECTRON CONJUGATED COMPOUND AND METHOD FOR PRODUCING THE PI-ELECTRON CONJUGATED COMPOUND | GOTO DAISUKE (JP) | 2014-06-26 | — | — | US | disclosed |
| US-20140175416-A1 | LEAVING SUBSTITUENT-CONTAINING COMPOUND, ORGANIC SEMICONDUCTOR MATERIAL, ORGANIC SEMICONDUCTOR FILM CONTAINING THE MATERIAL, ORGANIC ELECTRONIC DEVICE CONTAINING THE FILM, METHOD FOR PRODUCING FILM-LIKE PRODUCT, PI-ELECTRON CONJUGATED COMPOUND AND METHOD FOR PRODUCING THE PI-ELECTRON CONJUGATED COMPOUND | GOTO DAISUKE (JP) | 2014-06-26 | — | — | US | disclosed |
| US-8754399-B2 | Organic electroluminescence element, organic electroluminescence device, organic el display device, and organic el lighting | MITSUBISHI CHEMICAL CORPORATION (JP) | 2014-06-17 | — | — | US | disclosed |
| US-8754399-B2 | Organic electroluminescence element, organic electroluminescence device, organic el display device, and organic el lighting | MITSUBISHI CHEMICAL CORPORATION (JP) | 2014-06-17 | — | — | US | disclosed |
| US-20140163011-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140155431-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-06-05 | — | — | US | disclosed |
| US-20140155376-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2014-06-05 | — | — | US | disclosed |
| US-8741925-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-06-03 | — | — | US | disclosed |
| US-8735584-B2 | Protein kinase inhibitors and use thereof | MERCK PATENT GMBH (DE) | 2014-05-27 | — | — | US | disclosed |
| US-20140140953-A1 | SALTS OF BICYCLO-SUBSTITUTED PYRAZOLON AZO DERIVATIVES, PREPARATION METHOD AND USE THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2014-05-22 | — | — | US | disclosed |
| US-20140140953-A1 | SALTS OF BICYCLO-SUBSTITUTED PYRAZOLON AZO DERIVATIVES, PREPARATION METHOD AND USE THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2014-05-22 | — | — | US | disclosed |
| US-20140140953-A1 | SALTS OF BICYCLO-SUBSTITUTED PYRAZOLON AZO DERIVATIVES, PREPARATION METHOD AND USE THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2014-05-22 | — | — | US | disclosed |
| EP-2731953-A1 | TRICYCLIC INHIBITORS OF KINASES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Abbvie Inc. (US) | 2014-05-21 | — | — | EP | disclosed |
| US-8716297-B2 | Chemical entities to be used for Wee1 inhibition for the treatment of cancer | ABBVIE INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-20140121208-A1 | Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-05-01 | — | — | US | disclosed |
| EP-2725632-A1 | USE OF COMPOSITIONS COMPRISING POLYMERIC INERT BINDERS FOR THE FABRICAITON OF LIGHT-EMITTING DIODE | Merck Patent GmbH (DE) | 2014-04-30 | — | — | EP | disclosed |
| US-8710065-B2 | Tricyclic inhibitors of kinases | ABBVIE INC. (US) | 2014-04-29 | — | — | US | disclosed |
| US-8680296-B2 | Leaving substituent-containing compound, products produced using the same, and methods for producing the products | RICOH COMPANY, LTD. (JP) | 2014-03-25 | — | — | US | disclosed |
| US-8680296-B2 | Leaving substituent-containing compound, products produced using the same, and methods for producing the products | RICOH COMPANY, LTD. (JP) | 2014-03-25 | — | — | US | disclosed |
| US-20140051724-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-02-20 | — | — | US | disclosed |
| US-8642637-B2 | Salts of bicyclo-substituted pyrazolon azo derivatives, preparation method and use thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2014-02-04 | — | — | US | disclosed |
| US-8642637-B2 | Salts of bicyclo-substituted pyrazolon azo derivatives, preparation method and use thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2014-02-04 | — | — | US | disclosed |
| US-8642637-B2 | Salts of bicyclo-substituted pyrazolon azo derivatives, preparation method and use thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2014-02-04 | — | — | US | disclosed |
| US-8642582-B2 | Morpholinone compounds as factor IXa inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-02-04 | — | — | US | disclosed |
| US-20140024786-A1 | POLYIMIDE PRECURSOR COMPOSITION, ARTICLE PREPARED BY USING SAME, AND DISPLAY DEVICE INCLUDING THE ARTICLE | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2014-01-23 | — | — | US | disclosed |
| US-8629162-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-01-14 | — | — | US | disclosed |
| EP-2681221-A1 | TRICYCLIC INHIBITORS OF KINASES | AbbVie Inc. (US) | 2014-01-08 | — | — | EP | disclosed |
| EP-2350311-B1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | MADRIGAL PHARMACEUTICALS INC (US) | 2013-12-25 | — | — | EP | disclosed |
| US-8614327-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-12-24 | — | — | US | disclosed |
| US-20130331567-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-12-12 | — | — | US | disclosed |
| EP-2663565-A2 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | Sunovion Pharmaceuticals Inc. (US) | 2013-11-20 | — | — | EP | disclosed |
| US-20130253131-A1 | POLYMER, INK AND ORGANIC FILM | RICOH COMPANY, LTD. (JP) | 2013-09-26 | — | — | US | disclosed |
| US-20130253131-A1 | POLYMER, INK AND ORGANIC FILM | RICOH COMPANY, LTD. (JP) | 2013-09-26 | — | — | US | disclosed |
| EP-2640705-A2 | NOVEL ANTIVIRAL COMPOUNDS | Katholieke Universiteit Leuven (BE) | 2013-09-25 | — | — | EP | disclosed |
| US-20130245049-A1 | Novel Antiviral Compounds | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2013-09-19 | — | — | US | disclosed |
| US-20130245049-A1 | Novel Antiviral Compounds | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2013-09-19 | — | — | US | disclosed |
| US-20130245049-A1 | Novel Antiviral Compounds | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2013-09-19 | — | — | US | disclosed |
| EP-2074089-B1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2013-09-18 | — | — | EP | disclosed |
| US-20130225858-A1 | ARYLAMINE COMPOUND | RICOH COMPANY, LTD. (JP) | 2013-08-29 | — | — | US | disclosed |
| US-20130225858-A1 | ARYLAMINE COMPOUND | RICOH COMPANY, LTD. (JP) | 2013-08-29 | — | — | US | disclosed |
| US-20130225858-A1 | ARYLAMINE COMPOUND | RICOH COMPANY, LTD. (JP) | 2013-08-29 | — | — | US | disclosed |
| EP-1812416-B1 | ARYLSULFONYLMETHYL OR ARYLSULFONAMIDE SUBSTITUTED AROMATIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO KG (DE) | 2013-08-21 | — | — | EP | disclosed |
| US-8513239-B2 | Chiral cis-imidazolines | HOFFMANN-LA ROCHE INC. (US) | 2013-08-20 | — | — | US | disclosed |
| EP-2280933-B1 | 2 -AMINOTETRALIN DERIVATIVES AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE INC (US) | 2013-07-24 | — | — | EP | disclosed |
| US-20130165442-A1 | Modulators of ATP-Binding Cassette Transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130134402-A1 | ORGANIC ELECTROLUMINESCENCE ELEMENT, ORGANIC ELECTROLUMINESCENCE DEVICE, ORGANIC EL DISPLAY DEVICE, AND ORGANIC EL LIGHTING | MITSUBISHI CHEMICAL CORPORATION (JP) | 2013-05-30 | — | — | US | disclosed |
| US-20130134402-A1 | ORGANIC ELECTROLUMINESCENCE ELEMENT, ORGANIC ELECTROLUMINESCENCE DEVICE, ORGANIC EL DISPLAY DEVICE, AND ORGANIC EL LIGHTING | MITSUBISHI CHEMICAL CORPORATION (JP) | 2013-05-30 | — | — | US | disclosed |
| US-20130123507-A1 | BICYCLO-SUBSTITUTED PYRAZOLON AZO DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO. LTD. (CN) | 2013-05-16 | — | — | US | disclosed |
| US-20130123507-A1 | BICYCLO-SUBSTITUTED PYRAZOLON AZO DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO. LTD. (CN) | 2013-05-16 | — | — | US | disclosed |
| US-20130123507-A1 | BICYCLO-SUBSTITUTED PYRAZOLON AZO DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO. LTD. (CN) | 2013-05-16 | — | — | US | disclosed |
| EP-2571880-A1 | PYRROLO [2, 3 - B]PYRAZINE - 7 - CARBOXAMIDE DERIVATIVES AND THEIR USE AS JAK AND SYK INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-03-27 | — | — | EP | disclosed |
| US-20130035327-A1 | Modulators of ATP-Binding Cassette Transporters | VERTEX PHARMACEUTICALS INCORPORATED | 2013-02-07 | — | — | US | disclosed |
| US-8367710-B2 | Bicyclo-substituted pyrazolon azo derivatives, preparation process and pharmaceutical use thereof | JIANGSU HENGRUI MEDICINE CO. LTD. (CN) | 2013-02-05 | — | — | US | disclosed |
| US-8367710-B2 | Bicyclo-substituted pyrazolon azo derivatives, preparation process and pharmaceutical use thereof | JIANGSU HENGRUI MEDICINE CO. LTD. (CN) | 2013-02-05 | — | — | US | disclosed |
| US-8367710-B2 | Bicyclo-substituted pyrazolon azo derivatives, preparation process and pharmaceutical use thereof | JIANGSU HENGRUI MEDICINE CO. LTD. (CN) | 2013-02-05 | — | — | US | disclosed |
| WO-2013012681-A1 | TRICYCLIC INHIBITORS OF KINASES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | ABBOTT LABORATORIES (US) | 2013-01-24 | — | — | WO | disclosed |
| US-20130018045-A1 | New Chemical Entities To Be Used For Wee1 Inhibition For The Treatment Of Cancer | ABBOTT LABORATORIES (US) | 2013-01-17 | — | — | US | disclosed |
| US-8354427-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2013-01-15 | — | — | US | disclosed |
| EP-2254889-B1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MERCK PATENT GMBH (DE) | 2012-12-19 | — | — | EP | disclosed |
| EP-2532650-A2 | Modulators of ATP-binding cassette transporters | Vertex Pharmaceuticals Incorporated (US) | 2012-12-12 | — | — | EP | disclosed |
| US-20120309758-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-12-06 | — | — | US | disclosed |
| EP-2530075-A2 | Modulators of ATP-binding cassette transporters | Vertex Pharmaceuticals Incorporated (US) | 2012-12-05 | — | — | EP | disclosed |
| US-8324385-B2 | Diacylglycerol acyltransferase inhibitors | MADRIGAL PHARMACEUTICALS, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-8324242-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2012-12-04 | — | — | US | disclosed |
| WO-2012161812-A1 | TRICYCLIC INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2012-11-29 | — | — | WO | disclosed |
| EP-2522659-A2 | Modulators of ATP-binding cassette transporters | Vertex Pharmaceuticals Incorporated (US) | 2012-11-14 | — | — | EP | disclosed |
| US-20120273736-A1 | COMPOSITIONS COMPRISING POLYMERIC BINDERS | MERCK PATENT GMBH (DE) | 2012-11-01 | — | — | US | disclosed |
| EP-2517274-A1 | COMPOSITIONS COMPRISING POLYMERIC BINDERS | Merck Patent GmbH (DE) | 2012-10-31 | — | — | EP | disclosed |
| EP-2502914-A2 | Modulators of ATP-binding cassette transporters | Vertex Pharmaceuticals Incorporated (US) | 2012-09-26 | — | — | EP | disclosed |
| EP-2502902-A2 | Modulators of ATP-binding cassette transporters | Vertex Pharmaceuticals Incorporated (US) | 2012-09-26 | — | — | EP | disclosed |
| EP-2502913-A2 | Modulators of ATP-binding cassette transporters | Vertex Pharmaceuticals Incorporated (US) | 2012-09-26 | — | — | EP | disclosed |
| EP-2502912-A2 | Modulators of ATP-binding cassette transporters | Vertex Pharmaceuticals Incorporated (US) | 2012-09-26 | — | — | EP | disclosed |
| EP-2502911-A2 | Modulators of ATP-binding cassette transporters | Vertex Pharmaceuticals Incorporated (US) | 2012-09-26 | — | — | EP | disclosed |
| US-20120220572-A1 | TRICYCLIC INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2012-08-30 | — | — | US | disclosed |
| EP-2489659-A1 | Modulators of ATP-binding cassette transporters | Vertex Pharmaceuticals Incorporated (US) | 2012-08-22 | — | — | EP | disclosed |
| US-20120208806-A1 | Hsp90 Inhibitors | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2012-08-16 | — | — | US | disclosed |
| EP-2479175-A1 | Compounds and methods for treating dyslipidemia | Eli Lilly and Company (US) | 2012-07-25 | — | — | EP | disclosed |
| EP-2479175-A1 | Compounds and methods for treating dyslipidemia | Eli Lilly and Company (US) | 2012-07-25 | — | — | EP | disclosed |
| WO-2012096929-A2 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2012-07-19 | — | — | WO | disclosed |
| WO-2012096929-A2 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2012-07-19 | — | — | WO | disclosed |
| US-8222248-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-07-17 | — | — | US | disclosed |
| US-20120178748-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120178748-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120178748-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120164102-A1 | SALTS OF BICYCLO-SUBSTITUTED PYRAZOLON AZO DERIVATIVES, PREPARATION METHOD AND USE THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2012-06-28 | — | — | US | disclosed |
| US-20120164102-A1 | SALTS OF BICYCLO-SUBSTITUTED PYRAZOLON AZO DERIVATIVES, PREPARATION METHOD AND USE THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2012-06-28 | — | — | US | disclosed |
| US-20120165360-A1 | AMINO- AND AMIDO-AMINOTETRALIN DERIVATIVES AND RELATED COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-20120164102-A1 | SALTS OF BICYCLO-SUBSTITUTED PYRAZOLON AZO DERIVATIVES, PREPARATION METHOD AND USE THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2012-06-28 | — | — | US | disclosed |
| US-20120153271-A1 | LEAVING SUBSTITUENT-CONTAINING COMPOUND, ORGANIC SEMICONDUCTOR MATERIAL, ORGANIC SEMICONDUCTOR FILM CONTAINING THE MATERIAL, ORGANIC ELECTRONIC DEVICE CONTAINING THE FILM, METHOD FOR PRODUCING FILM-LIKE PRODUCT, PI-ELECTRON CONJUGATED COMPOUND AND METHOD FOR PRODUCING THE PI-ELECTRON CONJUGATED COMPOUND | RICOH COMPANY, LTD. (JP) | 2012-06-21 | — | — | US | disclosed |
| US-20120153271-A1 | LEAVING SUBSTITUENT-CONTAINING COMPOUND, ORGANIC SEMICONDUCTOR MATERIAL, ORGANIC SEMICONDUCTOR FILM CONTAINING THE MATERIAL, ORGANIC ELECTRONIC DEVICE CONTAINING THE FILM, METHOD FOR PRODUCING FILM-LIKE PRODUCT, PI-ELECTRON CONJUGATED COMPOUND AND METHOD FOR PRODUCING THE PI-ELECTRON CONJUGATED COMPOUND | RICOH COMPANY, LTD. (JP) | 2012-06-21 | — | — | US | disclosed |
| WO-2012065963-A2 | NOVEL ANTIVIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2012-05-24 | — | — | WO | disclosed |
| WO-2012065963-A2 | NOVEL ANTIVIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2012-05-24 | — | — | WO | disclosed |
| EP-2441457-A1 | SALTS OF BICYCLO-SUBSTITUTED PYRAZOLON AZO DERIVATIVES, PREPARATION METHOD AND USE THEREOF | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2012-04-18 | — | — | EP | disclosed |
| EP-2441457-A1 | SALTS OF BICYCLO-SUBSTITUTED PYRAZOLON AZO DERIVATIVES, PREPARATION METHOD AND USE THEREOF | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2012-04-18 | — | — | EP | disclosed |
| US-8153686-B2 | Amino- and amido-aminotetralin derivatives and related compounds as mu opioid receptor antagonists | THERAVANCE, INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-8133909-B2 | Heteroaromatic monoamides as orexinin receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2012-03-13 | — | — | US | disclosed |
| WO-2012012322-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-01-26 | — | — | WO | disclosed |
| US-20120015943-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACUTICALS, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| EP-2396316-A1 | QUINAZOLINONES AS PROLYL HYDROXYLASE INHIBITORS | Janssen Pharmaceutica, N.V. (BE) | 2011-12-21 | — | — | EP | disclosed |
| WO-2011144585-A1 | PYRROLO [2, 3 - B] PYRAZINE - 7 - CARBOXAMIDE DERIVATIVES AND THEIR USE AS JAK AND SYK INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-11-24 | — | — | WO | disclosed |
| US-20110288067-A1 | Pyrrolopyrazine Kinase Inhibitors | HENDRICKS ROBERT THAN (US) | 2011-11-24 | — | — | US | disclosed |
| EP-1761522-B1 | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | LILLY CO ELI (US) | 2011-10-12 | — | — | EP | disclosed |
| EP-1761522-B1 | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | LILLY CO ELI (US) | 2011-10-12 | — | — | EP | disclosed |
| US-8004824-B2 | Solid electrolytic capacitor element and solid electrolytic capacitor using same | MURATA MANUFACTURING CO., LTD. (JP) | 2011-08-23 | — | — | US | disclosed |
| EP-2350311-A1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | Via Pharmaceuticals, Inc. (US) | 2011-08-03 | — | — | EP | disclosed |
| WO-2011076325-A1 | COMPOSITIONS COMPRISING POLYMERIC BINDERS | MERCK PATENT GMBH (DE) | 2011-06-30 | — | — | WO | disclosed |
| US-20110135650-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2011-06-09 | — | — | US | disclosed |
| WO-2011044394-A1 | PURINE DERIVATIVES USEFUL AS HSP90 INHIBITORS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2011-04-14 | — | — | WO | disclosed |
| EP-2297102-A1 | HETEROAROMATIC MONOAMIDES AS OREXININ RECEPTOR ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2011-03-23 | — | — | EP | disclosed |
| US-20110059958-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2011-03-10 | — | — | US | disclosed |
| US-20110053906-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MERCK PATENT GMBH (DE) | 2011-03-03 | — | — | US | disclosed |
| WO-2011018987-A1 | DISPLAY DEVICE | 住友化学株式会社 (JP) | 2011-02-17 | — | — | WO | disclosed |
| EP-2280933-A1 | 2 -AMINOTETRALIN DERIVATIVES AS MU OPIOID RECEPTOR ANTAGONISTS | Theravance, Inc. (US) | 2011-02-09 | — | — | EP | disclosed |
| US-20110026190-A1 | SOLID ELECTROLYTIC CAPACITOR, METHOD FOR MANUFACTURING SAME, AND BASE FOR SOLID ELECTROLYTIC CAPACITOR | SHOWA DENKO K.K. (JP) | 2011-02-03 | — | — | US | disclosed |
| US-20100331384-A1 | GUANIDINE BASED COMPOUNDS | UNIVERSIDAD DEL PAIS VASCO/EUSKAL HERRIKO UNIBERTSITATEA (ES) | 2010-12-30 | — | — | US | disclosed |
| US-20100316601-A1 | BICYCLO-SUBSTITUTED PYRAZOLON AZO DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF | JIANGSU HENGRUI MEDICINE CO. LTD. (CN) | 2010-12-16 | — | — | US | disclosed |
| US-20100316601-A1 | BICYCLO-SUBSTITUTED PYRAZOLON AZO DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF | JIANGSU HENGRUI MEDICINE CO. LTD. (CN) | 2010-12-16 | — | — | US | disclosed |
| US-20100316601-A1 | BICYCLO-SUBSTITUTED PYRAZOLON AZO DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF | JIANGSU HENGRUI MEDICINE CO. LTD. (CN) | 2010-12-16 | — | — | US | disclosed |
| EP-2254889-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | Merck Patent GmbH (DE) | 2010-12-01 | — | — | EP | disclosed |
| US-20100284128-A1 | SOLID ELECTROLYTIC CAPACITOR ELEMENT AND SOLID ELECTROLYTIC CAPACITOR USING SAME | SHOWA DENKO K.K. (JP) | 2010-11-11 | — | — | US | disclosed |
| EP-2236500-A1 | BICYCLO-SUBSTITUTED PYRAZOLON AZO DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2010-10-06 | — | — | EP | disclosed |
| EP-2236500-A1 | BICYCLO-SUBSTITUTED PYRAZOLON AZO DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2010-10-06 | — | — | EP | disclosed |
| US-7786108-B2 | Compounds and method for treating dyslipidemia | ELI LILLY AND COMPANY (US) | 2010-08-31 | — | — | US | disclosed |
| US-7786108-B2 | Compounds and method for treating dyslipidemia | ELI LILLY AND COMPANY (US) | 2010-08-31 | — | — | US | disclosed |
| US-7786108-B2 | Compounds and method for treating dyslipidemia | ELI LILLY AND COMPANY (US) | 2010-08-31 | — | — | US | disclosed |
| WO-2010093727-A1 | QUINAZOLINONES AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-08-19 | — | — | WO | disclosed |
| US-20100204207-A1 | Compounds and Methods for Treating Dyslipidemia | CHEN XINCHAO | 2010-08-12 | — | — | US | disclosed |
| US-20100204207-A1 | Compounds and Methods for Treating Dyslipidemia | CHEN XINCHAO | 2010-08-12 | — | — | US | disclosed |
| US-20100204207-A1 | Compounds and Methods for Treating Dyslipidemia | CHEN XINCHAO | 2010-08-12 | — | — | US | disclosed |
| US-20100204226-A1 | QUINAZOLINONES AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-08-12 | — | — | US | disclosed |
| US-20100184739-A1 | Modulators of ATP-Binding Cassette Transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-07-22 | — | — | US | disclosed |
| US-7749992-B2 | Compounds and methods for treating dislipidemia | ELI LILLY AND COMPANY (US) | 2010-07-06 | — | — | US | disclosed |
| US-7745081-B2 | Diphenyl amine derivative, production method therefor and electrophotographic photoconductor | KYOCERA MITA CORPORATION (JP) | 2010-06-29 | — | — | US | disclosed |
| US-7745081-B2 | Diphenyl amine derivative, production method therefor and electrophotographic photoconductor | KYOCERA MITA CORPORATION (JP) | 2010-06-29 | — | — | US | disclosed |
| WO-2010056506-A1 | DIACYLGLYCEROL ACLYTRANSFERASE INHIBITORS | VIA PHARMACEUTICALS, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
| EP-2185503-A1 | MONOAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2010-05-19 | — | — | EP | disclosed |
| US-20100113782-A1 | Diacylglycerol Acyltransferase Inhibitors | MADRIGAL PHARMACEUTICALS, INC. | 2010-05-06 | — | — | US | disclosed |
| US-7697267-B2 | Capacitor and method for manufacturing same | SHOWA DENKO K.K. (JP) | 2010-04-13 | — | — | US | disclosed |
| US-20100016387-A1 | METHOD OF TREATMENT | BOSE AVIRUP | 2010-01-21 | — | — | US | disclosed |
| WO-2009153180-A1 | HETEROAROMATIC MONOAMIDES AS OREXININ RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-12-23 | — | — | WO | disclosed |
| US-20090312314-A1 | HETEROAROMATIC MONOAMIDES AS OREXININ RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-12-17 | — | — | US | disclosed |
| US-20090298876-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-12-03 | — | — | US | disclosed |
| EP-2116547-A1 | Substituted N-imidazo(2, 1-b) thiazole-5-sulfonamide derivatives as 5-TH6 ligands | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2009-11-11 | — | — | EP | disclosed |
| EP-2116546-A1 | Substituted N-phenyl-2,3-dihydroimidazo[2,1-b]thiazole-5-sulfonamide derivatives as 5-HT6 ligands | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2009-11-11 | — | — | EP | disclosed |
| US-20090264424-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. | 2009-10-22 | — | — | US | disclosed |
| US-20090264424-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. | 2009-10-22 | — | — | US | disclosed |
| US-20090264424-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. | 2009-10-22 | — | — | US | disclosed |
| WO-2009124022-A1 | 2 -AMINOTETRALIN DERIVATIVES AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2009-10-08 | — | — | WO | disclosed |
| US-20090247627-A1 | AMINO- AND AMIDO-AMINOTETRALIN DERIVATIVES AND RELATED COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-10-01 | — | — | US | disclosed |
| US-20090246820-A1 | COMPOUNDS USEFUL IN CFTR ASSAYS AND METHODS THEREWITH | VERTEX PHARMACEUTICALS INCORPORATED | 2009-10-01 | — | — | US | disclosed |
| EP-2101783-A2 | METHOD OF PREVENTING OR TREATING MYOCARDIAL ISCHEMIA | Novartis Ag (CH) | 2009-09-23 | — | — | EP | disclosed |
| WO-2009112445-A1 | METHOD OF INCREASING CELLULAR PHOSPHATIDYL CHOLINE BY DGAT1 INHIBITION | NOVARTIS AG (CH) | 2009-09-17 | — | — | WO | disclosed |
| US-20090227797-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-09-10 | — | — | US | disclosed |
| EP-1670768-B1 | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | LILLY CO ELI (US) | 2009-09-09 | — | — | EP | disclosed |
| EP-2098512-A1 | Compounds and methods for treating dyslipidemia | Eli Lilly & Company (US) | 2009-09-09 | — | — | EP | disclosed |
| WO-2009108670-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MERCK SERONO S.A. (CH) | 2009-09-03 | — | — | WO | disclosed |
| US-7582657-B2 | Treating inflammatory and neuropathic pain, headache, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, eye disorders, bladder disorders, psoriasis, skin disorders, asthma, herpes simplex | AMGEN INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-7582657-B2 | Treating inflammatory and neuropathic pain, headache, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, eye disorders, bladder disorders, psoriasis, skin disorders, asthma, herpes simplex | AMGEN INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-7582657-B2 | Treating inflammatory and neuropathic pain, headache, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, eye disorders, bladder disorders, psoriasis, skin disorders, asthma, herpes simplex | AMGEN INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-7579347-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-7579347-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-7579347-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2009-08-25 | — | — | US | disclosed |
| EP-2076489-A1 | ARYLSULFONAMIDYL TETRALIN DERIVATIVES AND USES THEREOF | F. Hoffmann-Roche AG (CH) | 2009-07-08 | — | — | EP | disclosed |
| WO-2009080818-A2 | GUANIDINE BASED COMPOUNDS | THE PROVOST, FELLOWS AND SCHOLARS OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN (IE) | 2009-07-02 | — | — | WO | disclosed |
| EP-2074089-A2 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2009-07-01 | — | — | EP | disclosed |
| US-20090111789-A1 | CHIRAL CIS-IMIDAZOLINES | HOFFMANN-LA ROCHE, INC. | 2009-04-30 | — | — | US | disclosed |
| US-7495103-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-02-24 | — | — | US | disclosed |
| WO-2009016087-A1 | MONOAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | WO | disclosed |
| US-20090036422-A1 | MONOAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
| US-20090012074-A1 | Arylsulfonylmethyl or arylsulfonamide substituted aromatic compounds suitable for treating disorders that respond to modulation of the Dopamine D3 receptor | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2009-01-08 | — | — | US | disclosed |
| US-20080316681-A1 | Capacitor and Method for Manufacturing Same | SHOWA DENKO K.K. (JP) | 2008-12-25 | — | — | US | disclosed |
| EP-1978533-A1 | CAPACITOR AND METHOD FOR MANUFACTURING SAME | Showa Denko K.K. (JP) | 2008-10-08 | — | — | EP | disclosed |
| WO-2008073865-A2 | METHOD OF PREVENTING OR TREATING MYOCARDIAL ISCHEMIA | NOVARTIS AG (CH) | 2008-06-19 | — | — | WO | disclosed |
| WO-2008048991-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2008-04-24 | — | — | WO | disclosed |
| US-20080071095-A1 | Cystic fibrosis transmembrane conductance | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-03-20 | — | — | US | disclosed |
| US-20080058377-A1 | Bicyclic Amide, Carbamate or Urea Derivatives as Vanilloid Receptor Modulators | BAYER HEALTHCARE AG (DE) | 2008-03-06 | — | — | US | disclosed |
| WO-2007147762-A1 | ARYLSULFONAMIDYL TETRALIN DERIVATIVES AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2007-12-27 | — | — | WO | disclosed |
| US-20070275314-A1 | Diphenyl amine derivative, production method therefor and electrophotographic photoconductor | KYOCERA MITA CORPORATION (JP) | 2007-11-29 | — | — | US | disclosed |
| US-20070275314-A1 | Diphenyl amine derivative, production method therefor and electrophotographic photoconductor | KYOCERA MITA CORPORATION (JP) | 2007-11-29 | — | — | US | disclosed |
| EP-1860095-A2 | Diphenylamine derivative, production method therefor and electrophotographic photoconductor | Kyocera Mita Corporation (JP) | 2007-11-28 | — | — | EP | disclosed |
| US-20070254869-A1 | Compounds And Methods For Treating Dislipidemia | ELI LILLY AND COMPANY (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070244095-A1 | S)-(3,5-Bistrifluoromethylbenzyl)-(1-cyclopentylmethyl-7-methyl-8-trifluoromethyl-2,3,4,5-tetrahydro-1H-benzo[b]azepin-5-yl)-(2-methyl-2H-tetrazol-5-yl)amine, for treating and/or preventing diseases related to abnormal cholesterol ester transfer protein activity such as atherosclerosis | ELI LILLY AND COMPANY | 2007-10-18 | — | — | US | disclosed |
| US-20070244095-A1 | S)-(3,5-Bistrifluoromethylbenzyl)-(1-cyclopentylmethyl-7-methyl-8-trifluoromethyl-2,3,4,5-tetrahydro-1H-benzo[b]azepin-5-yl)-(2-methyl-2H-tetrazol-5-yl)amine, for treating and/or preventing diseases related to abnormal cholesterol ester transfer protein activity such as atherosclerosis | ELI LILLY AND COMPANY | 2007-10-18 | — | — | US | disclosed |
| US-20070244095-A1 | S)-(3,5-Bistrifluoromethylbenzyl)-(1-cyclopentylmethyl-7-methyl-8-trifluoromethyl-2,3,4,5-tetrahydro-1H-benzo[b]azepin-5-yl)-(2-methyl-2H-tetrazol-5-yl)amine, for treating and/or preventing diseases related to abnormal cholesterol ester transfer protein activity such as atherosclerosis | ELI LILLY AND COMPANY | 2007-10-18 | — | — | US | disclosed |
| EP-1812416-A1 | ARYLSULFONYLMETHYL OR ARYLSULFONAMIDE SUBSTITUTED AROMATIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MADULATION OF THE DOPAMINE D3 RECEPTOR | Abbott GmbH & Co. KG (DE) | 2007-08-01 | — | — | EP | disclosed |
| EP-1780196-A2 | Pyridine derivatives for use as vanilloid receptor ligands | Amgen, Inc (US) | 2007-05-02 | — | — | EP | disclosed |
| EP-1780196-A2 | Pyridine derivatives for use as vanilloid receptor ligands | Amgen, Inc (US) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006040178-A9 | ARYLSULFONYLMETHYL OR ARYLSULFONAMIDE SUBSTITUTED AROMATIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MADULATION OF THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO KG (DE) | 2007-04-19 | — | — | WO | disclosed |
| EP-1764358-A2 | Cyclic amides as vanilloid receptor ligands and their use in treatments of inflammatory and neuropathic pain | Amgen, Inc (US) | 2007-03-21 | — | — | EP | disclosed |
| EP-1764358-A2 | Cyclic amides as vanilloid receptor ligands and their use in treatments of inflammatory and neuropathic pain | Amgen, Inc (US) | 2007-03-21 | — | — | EP | disclosed |
| EP-1761522-A1 | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | ELI LILLY AND COMPANY (US) | 2007-03-14 | — | — | EP | disclosed |
| US-20070027183-A1 | Inhibitors of microsomal triglyceride transfer protein and apo-B secretion | SURFACE LOGIX, INC. (US) | 2007-02-01 | — | — | US | disclosed |
| US-7157585-B2 | Serine protease inhibitors | TULARIK LIMITED (GB) | 2007-01-02 | — | — | US | disclosed |
| EP-1670768-A1 | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | ELI LILLY AND COMPANY (US) | 2006-06-21 | — | — | EP | disclosed |
| WO-2006040178-A1 | ARYLSULFONYLMETHYL OR ARYLSULFONAMIDE SUBSTITUTED AROMATIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MADULATION OF THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO.KG (DE) | 2006-04-20 | — | — | WO | disclosed |
| US-20060074075-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"), used for treating genetic disorders; respiratory system disorders | VERTEX PHARMACEUTICALS INCORPORATED | 2006-04-06 | — | — | US | disclosed |
| US-20060030618-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2006-02-09 | — | — | US | disclosed |
| WO-2006002342-A1 | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | ELI LILLY AND COMPANY (US) | 2006-01-05 | — | — | WO | disclosed |
| US-20050272931-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2005-12-08 | — | — | US | disclosed |
| EP-1463714-A4 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC (US) | 2005-10-19 | — | — | EP | disclosed |
| US-20050227986-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2005-10-13 | — | — | US | disclosed |
| US-20050215587-A1 | Serine protease inhibitors | LIVELY SARAH E | 2005-09-29 | — | — | US | disclosed |
| US-6916957-B2 | Serine protease inhibitors | TULARIK LIMITED (GB) | 2005-07-12 | — | — | US | disclosed |
| WO-2005037796-A1 | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | ELI LILLY AND COMPANY (US) | 2005-04-28 | — | — | WO | disclosed |
| EP-1463714-A2 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | Amgen Inc. (US) | 2004-10-06 | — | — | EP | disclosed |
| US-20030195201-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2003-10-16 | — | — | US | disclosed |
| WO-2003049702-A2 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2003-06-19 | — | — | WO | disclosed |
| EP-0614898-B1 | INDOLE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND MEDICINAL USE THEREOF | TORAY INDUSTRIES (JP) | 2003-05-07 | — | — | EP | disclosed |
| US-20030018059-A1 | Serine protease inhibitors | PROTHERICS MOLECULAR DESIGN LIMITED (GB) | 2003-01-23 | — | — | US | disclosed |
| EP-0657427-B1 | Tricyclic indole-2-carboxylic acid derivatives being selective antagonists of the NMDA receptor | SUMITOMO PHARMA (JP) | 2002-06-19 | — | — | EP | disclosed |
| US-6291470-B1 | DELTA-OPIOID ANTAGONIST HAVING HIGH SELECTIVITY AND ACTIVITY, THAT EXHIBITS IMMUNOSUPPRESSIVE ACTION, ANTIALLERGIC ACTION, ANTI-INFLAMMATORY ACTION AND BRAIN CELL-PROTECTING ACTION | TORAY INDUSTRIES, INC. (JP) | 2001-09-18 | — | — | US | disclosed |
| US-6087369-A | AN IMMUNOSUPPRESSIVE AGENT, ANTIALLERGIC AGENT, ANTI-INFLAMMATORY AGENT AND BRAIN CELL-PROTECTING AGENT | TORAY INDUSTRIES, LTD. (JP) | 2000-07-11 | — | — | US | disclosed |
| US-5852030-A | Indole derivatives, process for producing the same and medicinal uses of the same | TORAY INDUSTRIES, INC. (JP) | 1998-12-22 | — | — | US | disclosed |
| US-5530005-A | THERAPY FOR SKIN DISORDERS, AIDS, IMMUNOSUPPRESION DISEASES | SYNTEX (U.S.A.) INC. (US) | 1996-06-25 | — | — | US | disclosed |
| US-5496843-A | Tricyclic indole-2-carboxylic acid derivatives | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1996-03-05 | — | — | US | disclosed |
| US-5484588-A | Attracting and ingestion-stimulating agent for cockroach | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 1996-01-16 | — | — | US | disclosed |
| US-5475003-A | Antiinflammatory agent, immunosuppressive, antiallergens, bronchodilators, analgens | SYNTEX (U.S.A.) INC. (US) | 1995-12-12 | — | — | US | disclosed |
| EP-0657427-A1 | Tricyclic indole-2-carboxylic acid derivatives being selective antagonists of the NMDA receptor | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1995-06-14 | — | — | EP | disclosed |
| EP-0638237-A1 | ATTRACTANT AND FEEDING STIMULANT FOR COCKROACH | TAISHO PHARMACEUTICAL CO. LTD (JP) | 1995-02-15 | — | — | EP | disclosed |
| EP-0614898-A1 | INDOLE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND MEDICINAL USE THEREOF | TORAY INDUSTRIES, INC. (JP) | 1994-09-14 | — | — | EP | disclosed |
| EP-0598122-A1 | ATTRACTING AND INGESTION-STIMULATING AGENT FOR COCKROACH | TAISHO PHARMACEUTICAL CO. LTD (JP) | 1994-05-25 | — | — | EP | disclosed |
| EP-0598122-A1 | ATTRACTING AND INGESTION-STIMULATING AGENT FOR COCKROACH | TAISHO PHARMACEUTICAL CO. LTD (JP) | 1994-05-25 | — | — | EP | disclosed |
| JP-H05194107-A | ATTRACTING AND INGESTION-STIMULATING AGENT FOR COCKROACH | TAISHO PHARMACEUT CO LTD | 1993-08-03 | — | — | JP | disclosed |
| US-5225565-A | Antibacterial 3-(fused-ring substituted)phenyl-5β-amidomethyloxazolidin-2-ones | THE UPJOHN COMPANY (US) | 1993-07-06 | — | — | US | disclosed |
| WO-1993002554-A1 | ATTRACTING AND INGESTION-STIMULATING AGENT FOR COCKROACH | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 1993-02-18 | — | — | WO | disclosed |
| WO-1993002554-A1 | ATTRACTING AND INGESTION-STIMULATING AGENT FOR COCKROACH | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 1993-02-18 | — | — | WO | disclosed |
| US-5182403-A | Bactericides, treatment of AIDS | THE UPJOHN COMPANY (US) | 1993-01-26 | — | — | US | disclosed |
| US-5164510-A | Bactericides | THE UPJOHN COMPANY (US) | 1992-11-17 | — | — | US | disclosed |
| EP-0434714-A1 | IN POSITION 3 SUBSTITUTED-5-BETA-AMIDOMETHYL-OXAZOLIDIN-2-ONES | THE UPJOHN COMPANY (US) | 1991-07-03 | — | — | EP | disclosed |
| WO-1990002744-A1 | IN POSITION 3 SUBSTITUTED-5-BETA-AMIDOMETHYL-OXAZOLIDIN-2-ONES | THE UPJOHN COMPANY (US) | 1990-03-22 | — | — | WO | disclosed |
| EP-0359418-A1 | 5'-Indolinyl-5beta-amidomethyloxazolidin-2-ones, 3-(fused-ring substituted)phenyl-5beta-amidomethyloxazolidin-2-ones and 3-(nitrogen substituted)phenyl-5beta-amidomethyloxazolidin-2-ones | THE UPJOHN COMPANY (US) | 1990-03-21 | — | — | EP | disclosed |
| US-4695571-A | Tricyclic oxindole antiinflammatory agents | PFIZER INC. (US) | 1987-09-22 | — | — | US | disclosed |
| WO-1986001510-A1 | TRICYCLIC OXINDOLE ANTIINFLAMMATORY AGENTS | PFIZER INC. (US) | 1986-03-13 | — | — | WO | disclosed |
| US-4529736-A | Antidepressant | AMERICAN CYANAMID COMPANY (US) | 1985-07-16 | — | — | US | disclosed |
| EP-0109624-A2 | Process for producing shaped articles made from polyurethane-polyurea which may be cellular | BASF Aktiengesellschaft (DE) | 1984-05-30 | — | — | EP | disclosed |
| EP-0100426-A1 | 3a-(substituted-phenyl)-hexaloctahydro-4,7-alkanoisoindoles | AMERICAN CYANAMID COMPANY (US) | 1984-02-15 | — | — | EP | disclosed |
| US-4294578-A | ANTHRAQUINONE DYES, POLYAMIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1981-10-13 | — | — | US | disclosed |
| US-4264511-A | FOR DYEING POLYESTERS AND AS CHEMICAL INTERMEDIATE FOR DYESTUFF | BAYER AKTIENGESELLSCHAFT (DE) | 1981-04-28 | — | — | US | disclosed |
| EP-0005474-B1 | ANTHRAQUINONE COMPOUNDS, PROCESS FOR PREPARING THEM AND THEIR USE FOR DYEING AND PRINTING SYNTHETIC MATERIALS | BAYER AG (DE) | 1980-11-12 | — | — | EP | disclosed |
| US-4085268-A | Disubstituted s-triazines | ARMSTRONG CORK COMPANY (US) | 1978-04-18 | — | — | US | disclosed |
| US-4049811-A | MICROBIOCIDES | BOEHRINGER MANNHEIM G.M.B.H. (DT) | 1977-09-20 | — | — | US | disclosed |
| US-3966743-A | ANTIMICROBIAL | BOEHRINGER MANNHEIM G.M.B.H. (DT) | 1976-06-29 | — | — | US | disclosed |
| US-3966743-A | ANTIMICROBIAL | BOEHRINGER MANNHEIM G.M.B.H. (DT) | 1976-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190144450-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | ADRA2A 743/4885ADRA2B 469/4885ADRA2C 902/4885 |
| US-20150031722-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | ADRA2A 743/4885ADRA2B 469/4885ADRA2C 902/4885 |
| US-20050272931-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | ADRA2A 219/4885ADRA2B 248/4885ADRA2C 240/4885 |
| US-20130018045-A1 | New Chemical Entities To Be Used For Wee1 Inhibition For The Treatment Of Cancer | WEE1, WEE2, CCNE1 | ADRA2A 4456/4885ADRA2B 4193/4885ADRA2C 4150/4885 |
| US-20060030618-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | ADRA2A 219/4885ADRA2B 248/4885ADRA2C 240/4885 |
| US-20050215587-A1 | Serine protease inhibitors | PRSS1, TPSAB1, CMA1 | ADRA2A 1200/4885ADRA2B 1719/4885ADRA2C 2090/4885 |
| US-20130123507-A1 | BICYCLO-SUBSTITUTED PYRAZOLON AZO DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF | THPO, MPL, TEK | ADRA2A 1191/4885ADRA2B 729/4885ADRA2C 752/4885 |
| US-11891369-B2 | Compounds for binding proprotein convertase subtilisin/kexin type 9 | PCSK9, PCSK6, PCSK7 | ADRA2A 4050/4885ADRA2B 3067/4885ADRA2C 3281/4885 |
| US-10822352-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders | CFD, F12, F3 | ADRA2A 1045/4885ADRA2B 1013/4885ADRA2C 641/4885 |
| US-20170066783-A1 | Aryl, Heteroaryl, and Heterocyclic Compounds for Treatment of Medical Disorders | CFD, F12, F3 | ADRA2A 1045/4885ADRA2B 1013/4885ADRA2C 641/4885 |
| US-20230287005-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, F12, F3 | ADRA2A 1122/4885ADRA2B 1065/4885ADRA2C 626/4885 |
| US-10011612-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders | CFD, F12, F3 | ADRA2A 1045/4885ADRA2B 1013/4885ADRA2C 641/4885 |
| US-10696611-B2 | Adamantane derivative compound | ADAM8, BACE1, CYP17A1 | ADRA2A 89/4885ADRA2B 189/4885ADRA2C 158/4885 |
| US-20170283347-A1 | NOVEL ADAMANTANE DERIVATIVE COMPOUND | ADAM8, CYP17A1, ADAM10 | ADRA2A 76/4885ADRA2B 128/4885ADRA2C 121/4885 |
| US-20180030005-A1 | TETRAHYDRONAPHTHYRIDINE, BENZOXAZINE, AZA-BENZOXAZINE AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE | RORB, RORA, RORC | ADRA2A 132/4885ADRA2B 153/4885ADRA2C 65/4885 |
| US-20130165442-A1 | Modulators of ATP-Binding Cassette Transporters | CFTR, ABCB1, ABCC2 | ADRA2A 743/4885ADRA2B 469/4885ADRA2C 902/4885 |
| US-20200253958-A1 | PHENYLPIPERAZINE PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) MODULATORS AND THEIR USE | PCSK9, LDLR, PCSK7 | ADRA2A 2777/4885ADRA2B 2993/4885ADRA2C 2282/4885 |
| US-12110292-B2 | Ligands to cereblon (CRBN) | CRBN, CRKL, CDR2 | ADRA2A 4137/4885ADRA2B 3724/4885ADRA2C 4085/4885 |
| US-20100184739-A1 | Modulators of ATP-Binding Cassette Transporters | CFTR, ABCB1, ABCC2 | ADRA2A 743/4885ADRA2B 469/4885ADRA2C 902/4885 |
| US-20110135650-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | SERPINC1, F9, F8 | ADRA2A 4064/4885ADRA2B 4185/4885ADRA2C 4570/4885 |
| US-20110288067-A1 | Pyrrolopyrazine Kinase Inhibitors | SYK, ZAP70, JAK2 | ADRA2A 3841/4885ADRA2B 3383/4885ADRA2C 3651/4885 |
| US-20150298108-A1 | METHOD FOR PREPARING METHYL ACETATE | EHMT2, EHMT1, DNMT1 | ADRA2A 752/4885ADRA2B 1598/4885ADRA2C 1053/4885 |
| US-20100204226-A1 | QUINAZOLINONES AS PROLYL HYDROXYLASE INHIBITORS | P4HA1, EGLN3, EGLN2 | ADRA2A 3327/4885ADRA2B 2969/4885ADRA2C 2701/4885 |
| US-10172863-B2 | Purine derivatives useful as HSP90 inhibitors | XDH, HSP90B1, HSP90AA1 | ADRA2A 2067/4885ADRA2B 2106/4885ADRA2C 1559/4885 |
| US-20100316601-A1 | BICYCLO-SUBSTITUTED PYRAZOLON AZO DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF | THPO, MPL, TEK | ADRA2A 1191/4885ADRA2B 729/4885ADRA2C 752/4885 |
| US-20100113782-A1 | Diacylglycerol Acyltransferase Inhibitors | DGAT2, DGAT1, MOGAT2 | ADRA2A 2033/4885ADRA2B 2252/4885ADRA2C 1943/4885 |
| US-20030195201-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | ADRA2A 208/4885ADRA2B 249/4885ADRA2C 228/4885 |
| US-20140343315-A1 | Modulators of ATP-Binding Cassette Transporters | CFTR, ABCB1, ABCC2 | ADRA2A 743/4885ADRA2B 469/4885ADRA2C 902/4885 |
| US-20140155431-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | ADRA2A 743/4885ADRA2B 469/4885ADRA2C 902/4885 |
| US-20210292325-A1 | LIGANDS TO CEREBLON (CRBN) | CRBN, CRKL, CDR2 | ADRA2A 4137/4885ADRA2B 3724/4885ADRA2C 4085/4885 |
| US-20090227797-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | ADRA2A 743/4885ADRA2B 469/4885ADRA2C 902/4885 |
| US-20140343098-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | ADRA2A 743/4885ADRA2B 469/4885ADRA2C 902/4885 |
| US-20210002215-A1 | HEAT SENSITIVE RECORDING MATERIAL AND COLOR DEVELOPER | SCN1A, NCS1, SCN4A | ADRA2A 3140/4885ADRA2B 3146/4885ADRA2C 2102/4885 |
| US-20240343707-A1 | SUBSTITUTED PHENYL ETHYNYL PYRIMIDINES AS POTENT INHIBITORS OF ALPHAVIRUSES | PRNP, PNP, ZC3HAV1 | ADRA2A 3374/4885ADRA2B 3671/4885ADRA2C 3117/4885 |
| US-20140329814-A2 | Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases | CFTR, SLC26A4, ABCB11 | ADRA2A 993/4885ADRA2B 546/4885ADRA2C 522/4885 |
| US-11384055-B2 | Glycolate oxidase inhibitors for the treatment of disease | XDH, PNPO, AGXT | ADRA2A 4108/4885ADRA2B 3529/4885ADRA2C 3839/4885 |
| US-20120153271-A1 | LEAVING SUBSTITUENT-CONTAINING COMPOUND, ORGANIC SEMICONDUCTOR MATERIAL, ORGANIC SEMICONDUCTOR FILM CONTAINING THE MATERIAL, ORGANIC ELECTRONIC DEVICE CONTAINING THE FILM, METHOD FOR PRODUCING FILM-LIKE PRODUCT, PI-ELECTRON CONJUGATED COMPOUND AND METHOD FOR PRODUCING THE PI-ELECTRON CONJUGATED COMPOUND | F12, C1S, PYM1 | ADRA2A 4081/4885ADRA2B 4279/4885ADRA2C 4075/4885 |
| US-20140187770-A9 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | ADRA2A 743/4885ADRA2B 469/4885ADRA2C 902/4885 |
| US-20190144464-A1 | BIGUANIDE COMPOUNDS AND USE THEREOF | GCKR, GCG, SLC5A2 | ADRA2A 3954/4885ADRA2B 3593/4885ADRA2C 3346/4885 |
| US-20210032214-A1 | COMPOUNDS FOR BINDING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 | PCSK9, PCSK6, PCSK7 | ADRA2A 4310/4885ADRA2B 3340/4885ADRA2C 3633/4885 |
| US-11149011-B2 | Compounds and methods for IDO and TDO modulation, and indications therefor | IDO1, TDO2, IDO2 | ADRA2A 1773/4885ADRA2B 1571/4885ADRA2C 1867/4885 |
| US-20150065487-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | ADRA2A 743/4885ADRA2B 469/4885ADRA2C 902/4885 |
| US-10662192-B2 | Modulators of ATP-binding cassette transporters | CFTR, ABCB1, ABCC2 | ADRA2A 743/4885ADRA2B 469/4885ADRA2C 902/4885 |
| US-11084824-B2 | Pyrazolopyrimidine derivatives, preparation method thereof, and pharmaceutical composition for use in preventing or treating cancer, autoimmune disease and brain disease containing the same as an active ingredient | BTK, SYK, LCK | ADRA2A 4550/4885ADRA2B 4190/4885ADRA2C 3722/4885 |
| US-20080058377-A1 | Bicyclic Amide, Carbamate or Urea Derivatives as Vanilloid Receptor Modulators | NMUR1, CNR1, AVPR1A | ADRA2A 235/4885ADRA2B 416/4885ADRA2C 562/4885 |
| US-20030018059-A1 | Serine protease inhibitors | TPSAB1, PRSS1, SERPINB1 | ADRA2A 2337/4885ADRA2B 2418/4885ADRA2C 2451/4885 |
| US-11084784-B2 | ROR-gamma modulators and uses thereof | RORB, RORA, RORC | ADRA2A 260/4885ADRA2B 192/4885ADRA2C 221/4885 |
| US-20090111789-A1 | CHIRAL CIS-IMIDAZOLINES | FOXM1, CCNE1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | ADRA2A 1456/4885ADRA2B 1969/4885ADRA2C 1339/4885 |
| US-20230130176-A1 | ORGANIC MOLECULES FOR OPTOELECTRONIC DEVICES | C1R, F12, ORC3 | ADRA2A 2264/4885ADRA2B 2397/4885ADRA2C 1874/4885 |
| US-20090312314-A1 | HETEROAROMATIC MONOAMIDES AS OREXININ RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPSR1 | ADRA2A 103/4885ADRA2B 127/4885ADRA2C 118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.